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P-FNA, P-Funaltrexamine hydrochloride
GDP, guanosine-5'-diphosphate
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Neurotransmetter:
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Administration routes:
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i.t., intrathecal
s.c., subcutaneous
Others:
ANOVA, analysis ofvariance
CFA, complete Freund's adjuvant
CNS, central nervous system
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EDso, 500/o ofthe effective dose
Emax, maximum activation
FBC, femur bone cancer
GPCR, G-protein-coupled receptor
ICso, concentration of500/o inhibition
IS, internal standard
LLOQ, lower limit of quantification
MPE, maximum possible effect
MRM, molecular reaction monitoring
MV, minute volume
PK/PD, pharmacokineticslpharmacodynamics
QC, quality control
RR, respiratory rates
RSD, relative standard deviation
S.E.M., standard error ofmean
TV, tidal volume
                             General Introduction
Opioids therapy
      Opioids have been prescribed to manage moderate to severe pain due to cancer or
non-cancer conditions such as chronic inflammatory and post-operative pain. Although
agonists for the p-opioid receptor (MOR), such as morphine, oxycodone, and fentanyl, are
effective to relieve moderate to severe pain, the use ofstrong opioids is often accompanied by
several adverse effects including constipation, emesis, drowsiness, sedation, and respiratory
depression. These adverse effects limit the amount of opioid that can be prescribed for
effective pain management.
      Among the opioid-induced adverse effects, constipation is the most common during
long-term opioid therapy. Constipation occurs in approximately 90 O/o ofpatients taking opioid
chronically 93), and unlike emesis, which generally disappears within a few weeks ofopioid
treatment, tolerance rarely develops in the case of constipation.
      Drowsiness, catatonia, or behavioral inhibition is the adverse effect observed in
patients taking relatively high doses of opioids, and approximately 7-1O O/o ofpatients
receiving strong opioids for cancer pain have persistent sedation related to their opioid
medication 7). Opioid-induced motor dysfunction and sedation significantly affect the quality
of a patient's life.
      Among the opioid-induced adverse effects, respiratory depression is considered the
most serious adverse effect 47' 66). Because respiratory depression may lead to a
life-threatening incident, it is extremely important to know an appropriate opioid dose for
each patient.
p Opioid receptor (MOR)
      Most strong opioids are MOR agonists, and several studies have addressed the
pharmacological mechanism underlying the actions of opioids. MORs are expressed in
several brain regions that modulate ascending pain signal transmission from peripheral
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nociceptive sensory neurons to the central nervous system (CNS), including the spinal cord,
periaqueductal grey matter (PAG), lateral thalamus, and mediodorsal thalamus 2' ii). The
MOR belongs to the large G-protein-coupled receptor (GpcR) superfamily 9• i3• 43• 50• 75• 95).
Binding of a MOR agonist changes the receptor conformation allosterically, leading to the
activation ofGi-proteins. Since a MOR agonist induces the binding of
guanosine-5Lo-(3-[35S]thio)triphosphate ([35s]GTpyS) to G-proteins, measuring [35S]GTPyS
binding to the MOR in pain-related brain regions is valuable for assessing functional changes
in the MOR induced by opioid agonists 33• 60).
Oxycodone
      Most ofthe opioids used clinically have been classified as MOR agonists. However,
recent studies have shown that these MOR agonists and metabolites have interesting
pharmacological differences 36' 37' 76). oxycodone has been used in clinical since 1917.
Oxycodone, which is a semi-synthetic opioid analgesic derived from the naturally occurring
alkaloid, thebain, has good oral bioavailability and seems to provide analgesic action that is as
potent as that ofmorphine. It has been demonstrated that both oxycodone and its active
metaboiite showed MOR agonistic activities 36). Several clinical studies have suggested that
oxycodone may be usefu1 for the treatment ofneuropathic pain 80' 96) and bone cancer pain 3' 4'
i7, 22, 27, 86, 96• 97). Although oxycodone has been clinically used for many yearS, itS
pharmacological properties are still very poorly characterized.
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                               Aim and Scope
      The aim of the present study was to investigate the differential MOR activation
profiles of oxycodone and morphine in chronic pain models, using behavioural,
neurochemical and biochemical experiments.
      The specific aims of the proposed research are:
In chapter 1:
      The purpose of this chapter was to investigate whether pharmacological (adverse
effect) profiles differ among MOR agonists (oxycodone, morphine and fentanyl) under
controlled experimental setting. Oxycodone, morphine and fentanyl were subcutaneously
administered to rats, and the relative plasma concentrations for constipation, behavioral
inhibition and respiratory depression and for anti-nociceptive effect were examined in each
opioid.
In chapter 2:
      The aim of the chapter 2 was to further compare pharmacological profiles ofmorphine
and oxycodone following sciatic nerve ligation and investigate the mechanisms underlying
less sensitivity to morphine under a neuropathic pain-like state.
In chapter 3:
      The chapter 3 investigated the mechanism underlying the unique analgesic profile of
oxycodone by comparing it with morphine in a bone cancer pain model. One potential
mechanism -differential activation ofthe MOR by oxycodone and morphine under the bone
cancer pain-was observed in this model.
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                                   Ethics
      The present study in chapter 2 was conducted in accordance with the Guiding
Principles for the Care and Use of Laboratory Animals Hoshi University, as adopted by the
Committee on Animal Research ofHoshi University. Procedures in chapter 1 and 3 for the
animal experiments were approved by the Animal Care and Use Committee of Shionogi
Research Laboratories, Osaka, Japan in agreement with the internal guidelines for animal
experiments and in adherence to the ethics policy ofShionogi & Co. Every effort was made to
minimize the numbers and any suffering of animals used in the following experiments.
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                        Chapter 1
Distinct relations among plasma concentrations required for different
pharmacological effects in oxycodone, morphine and fentanyl
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                                Introduction
      While those opioid-induced adverse effects are resulted from pharmacological action
ofthe MOR activation, the clinically-used MOR agonists such as morphine, oxycodone, and
fentanyl appear to exhibit different adverse effect profiles. For example, the incidence of
adverse intestinal effects are relatively lower in fentanyl treatment, and the adverse intestinal
effect of morphine was suggested to be severe compared with that induced by oxycodone in a
clinical setting 2i' 53' 67). Although such difference may be resulted from distinct
pharmacological action ofrespective opioid agonists, precise analysis is limited due to several
reasons in the clinical observations. First, it is generally difficult to compare adverse effects
among opioids relative to equianalgesic concentrations. Second, the route of administration
(e.g. oral, subcutaneous or transdermal administration), which potentially affects
pharmacological effects, varies in a clinical setting. Third, patient background such as gender,
age, ethnic origin or genetic backgrounds are variable. Moreover, patients exhibit
intra-individual variability such as disease progression, increase in nociception, drug-drug
interactions, or emotional status.
      I therefore investigated whether pharmacological profiles differ among MOR agonists
under controlled experimental setting. Oxycodone, morphine, and fentanyl were
subcutaneously administered to rats, and the relative plasma concentrations for constipation,
behavioral inhibition and respiratory depression and for anti-nociceptive effect were
examined in each opioid.
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                             Materials and Methods
Animals
      Male SD rats (180-230 g) (CLEAJapan, Inc., Tokyo, Japan), 6-7 weeks old ofage,
were used in the present study. Animals were housed in a room maintained at 23 Å} 10C with
12 hr light-dark cycles. Food and water were available ad libitum. The protocols ofthe
present study were approved by the Institutional Animal Care and Use Committee of Shionogi
Research Laboratories, Osaka, Japan.
Assessment of anti-nociceptive effect
      The anti-nociceptive effects of oxycodone, morphine, and fentanyl were detemiined
by the tail-flick test (UGO-BASILE, Comerio, VA, Italy). The intensity ofthe heat stimulus
was adjusted so that the animal flicked its tail within 2-4 s after the application ofthe
stimulus. Anti-nociceptive effect was expressed as a percentage of the maximum possible
effect (MPE) and was calculated by (Ti - To) Å~ 1OO 1 (T2 - To), where To and Ti are the
tail-flick latencies before and after the administration of opioid agonist, respectively, and T2 is
the cut-off time (set at 1O s) in the tests to avoid damage to the tail.
Assessment of constipation
      A castor oil-induced diarrhea model was used to evaluate constipation effects of
oxycodone, morphine, and fentanyl. Diarrhea was assessed by visual inspection of feces at
several different time points after castor oil challenge (2 mLlanimal, p.o.) in rats. The rat was
placed in a clear plastic observation box and allowed to habituate for a period of 15 min.
Castor oil was administered at 5, 15, or 30 min before the subcutaneous administration of
oxycodone (O.56 mgtkg), morphine (O.56 mglkg), or fentanyl (O.O1 mgtkg). Degree of the
diarrhea was inspected at 75 min after castor oil administration and scored as follows: 2,
severe diarrhea; 1, mild diarrhea; O, no diarrhea. The inhibition ofcastor oil-induced diarrhea
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by opioid was scored as follows: 2, OO/o response; 1, 500/o response; O, 1000/o response. The
constipation effect ofthe opioid treatment was shown as O/o MPE, where 1000/o MPE is a score
ofO in all animals in response to the opioid treatment. For evaluation ofthe dose-response
effects ofthe opioids, castor oil was administered 15 min before the subcutaneous
administration ofoxycodone (O.1-1 mglkg), morphine (O.17-1 mglkg), or fentanyl
(O.O03-O.O17 mg/kg).
Assessment of behavioral inhibition
      Locomotor activity was measured by an ambulometer (SCANET MV- 1O). Briefly,
each rat was placed in a round activity cage. Any slight tilt of the activity cage caused by
horizontal movement of the animal was detected by microswitches. Total activity counts were
automatically recorded during 1O-20 min after drug administration. The inhibition of
behavioral response was expressed as a O/o MPE, which was calculated as (Ti - To) Å~ 1OO 1 (T2
-
 To), where To is the mean ofthe total activity in the saline (control) group, Ti is the total
activity ofeach animal treated with opioid, and T2 is the mean ofthe total activity ofthe
group treated with the maximal dose ofthe respective opioid.
Assessment of respiratory response
      Respiratory response was measured by using a whole-body plethysmography system
(EMMS, Hants, UK and NOTOCORD SYSTEMS, Croissy Sur Seine, France) with a
continuous flow of dry gas through a reference and a measurement chamber (PLY320, EMMS,
UK). The flow and composition ofthe gas were set by a bias fiow generator (AIRI10,
Information & Display Systems, Ltd., UK), so that continuous measurement ofrespiratory
variables was possible in unanesthetized rats without unintended decrease in oxygen or
accumulation ofcarbon dioxide inside the chamber. The chambers were kept at room
temperature (22-240C). The rats were placed in the measurement chamber for habituation (20
15
min x 3 times) before starting data acquisition. Because movements such as paw shakes,
headshakes, body shakes, rearing, grooming, climbing, or vocalization inside the chamber
resulted in artifacts in the pletysmographic signals, the periods without such artifacts were
analysed. I used the animals that showed a respiratory rate of 1OO-150 countlmin in pre-tests.
The respiratory rates (countlmin; RR) ofeach rat at approximately 15 min after drug
administration were determined based on the number ofbreaths for a period of 1-2 min. The
tidal volume (mLlkg; TV) was calculated per breath, and minute volume (mLlkglmin; MV)
was calculated from the data of RR and TV using the software on the whole-body
plethysmography system. The inhibition of this respiratory response was expressed as a O/o
MPE, which was calculated as (Ti - To) Å~ 1001(Ti), where To and Ti are MV latencies before
and after the administration ofeach opioid, respectively.
Drugs
      Oxycodone hydrochloride and morphine hydrochloride were from Shionogi
Pharmaceutical Co., Inc. (Osaka, Japan), and fentanyl citrate was obtained from Sankyo
(Fentanest, an injection form: Sankyo, Tokyo, Japan) and Tyco Healthcare (a powder forrn:
Tyco Healthcare, Tokyo, Japan). Fentanest was used for the tail-fiick test, the castor oil
diarrhea test, and the behavioral inhibition test, and the powder form of fentanyl citrate was
used for the respiratory inhibition test, as higher concentrations of fentanyl citrate than of
Fentanest were required for the respiratory response study. All drugs were dissolved in O.90/o
physiological saline (Otsuka Pharmaceutical Co., Inc., Tokyo, Japan) for in vivo experiments
and administered in a volume ofO.2 mLllOO g.
Measurement of plasma and brain opioid concentrations
(Calibration standards and quality control (QC) samples for quantitation method)
      The separate stock solutions for the calibration standards and QC samples were
prepared by dissolving each component in acetonitrilelwater (1:1, vlv) and mixing to prepare
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the working stock solutions. The working stock solutions were diluted with acetonitrilelwater
(1: 1, vlv) to prepare working standard solutions. The calibration standards and QC samples
were prepared by combining working standard solution with pooled control plasma. The
amount ofworking standard solution added to the plasma was 50/o ofthe plasma volume. The
analytical calibration ranges in rat plasma for oxycodone and morphine were 20.0 to 1OOOO
nglmL, and fentanyl was 2.00 to 1OOO nglmL or O.5-1000 nglmL.
(Measurement of rat plasma concentration of oxycodone, morphine, and fentanyl)
      Rat plasma samples were deproteinized with acetonitrilelmethanol (7:3, vlv)
containing internal standard and analyzed by LC-MSIMS. Rats were subcutaneously
administered oxycodone (O.3-10 mglkg), morphine (O.3-30 mglkg), or fentanyl (O.O1-1
mglkg). Blood samples were collected from an indwelling arterial cannula at 5, 15 and 60 min
after drug administration and transferred into the ice-cold polypropylene tubes. The
samples were centrifuged at 3,OOOx g for 10 min at 40C. The obtained plasma samples were
subsequently transferred into 2.0-mL polypropylene tubes and stored frozen at -800C until the
assay. On the day ofthe assay, frozen samples were thawed at room temperature and vortex
mixed. Thirty pL of each sample were then transferred to polypropylene tubes, and 21O pL of
acetonitrilelmethanol (7:3, vlv) containing internal standard were added. The solution was
mixed for 3 min and then centrifuged at 1,700Å~ g for 5 min at 250C to obtain the supernatant.
The supernatant was transferred to the collection vial containing of acetonitrilelmethanol (7:3,
vlv) and mixed. The assay solutions were stored at 1OOC in the autosampler until injection and
were injected 1O ptL into the LC-MSIMS system.
(LC-MSIMS conditions)
      The LC systems used were LC-20AD series (Shimadzu Corporation, Japan) or
NANOSPACE system (Shiseido, Japan). Separations were performed using a 150 Å~ 2.0-mm
i.d. TSK-Gel VMPAK-25 (TOSOH CORPORATION, Japan). The analytes were separated
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using an isocratic elution profiIe composed of elution (1O m mollL ammonium acetate 1
acetonitrile (1:1, vlv)). A flow rate ofO.2 mllmin was used. The column temperature was
maintained at 300C. The analytes were detected by positive-mode electrospray ionization
using a API-4000 or API-5000 triple-quadrupole mass spectrometer (AB SCIEX, Japan)
equipped with a TurbolonSpray ion source. The operating parameters ofthe ion source,
including analyte-dependent and source-dependent parameters, were optimized to obtain the
optimum performance from the mass spectrometer for the analysis ofoxycodone, morphine,
and fentanyl. The source-dependent parameters for the three analytes consisted ofcollision
gas, curtain gas, ion spray gas 1 and 2, ion spray voltage, and the temperature ofthe heater
gas, with optimum values of 1O, 10, 70, 90, and 5 kV and 600oC, respectively. The mass
spectrometer was operated at unit mass resolution for both Q1 and Q3 in molecular reaction
monitoring (MRM) mode. The analyte-dependent parameters were also tuned to obtain the
maximum detector response (Table 1). Data were acquired and processed using Analyst
version 1.4.2 software.
(Materials and reagents for LC-MSIMS analyses)
      Oxycodone hydrochloride and morphine hydrochloride were obtained from Shionogi
Pharrnaceutical Co., lnc. (Osaka, Japan). Fentanyl injection (fentanyl citrate solution, O.1
mg12 mL as fetanyl) supplied from Daiichi Sankyo Company, Ltd. was used as the standard
solution for measurement ofplasma concentrations. The internal standard (IS),
N-etylnormorphine, was purchased from Salford Ultrafine Chemicals and Research, Ltd.
Acetonitrile and methanol were ofHPLC grade, and ammonium acetate was of analytical
grade purchased from Kanto Chemical Co,, Inc. Water was dispensed in-house from a
Millipore water distribution system.
(Measurement ofrat plasma and brain concentrations ofoxycodone, morphine, and fentanyl
for pharmacokinetics 1 pharmacodynamics (PKIPD) analyses)
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      Rats were subcutaneously administered oxycodone (1 or 2 mg!kg), morphine (3 or 6
mglkg), or fentanyl (O.03 or O.06 mg/kg). Blood samples and whole brain without
cerebellum samples were collected at 15, 30, 60, 120 and 180 min after drug administration.
The plasma samples were centrifuged at 3,OOOx g for 10 min at 40C, and the brain sampled
were homogenized in saline solution. The obtained plasma and brain samples were stored
frozen at -800C until the assay. The opioid concentrations in the plasma and brain samples
were determined according to the similar method to the one described above. The distribution
ratio between brain and plasma was expressed as a brain Kp value, which was calculated as Ti
1 T2, where Ti is the brain concentration (nglg) and T2 is the plasma concentration (nglmL) at
respective timings after the opioid administration.
Statistical analysis
      The data were expressed as the mean Å} S.E.M. The GraphPad Prism 4.0 program was
used to obtain concentration-response curves for the pharmacological responses. The 500/o
effective dose (EDso) and 500/o effective plasma concentration (ECso) values were calculated
based on the inversion ofestimation in the regression analysis. The statistical significance of
differences among groups was assessed with a two-way ANOVA followed by Dunnett's
multiple comparison test.
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                                  Results
Anti-nociceptive effects of oxycodone, morphine and fentanyl
      In the tail-flick test, oxycodone (O.17-3 mglkg), morphine (O.56-1O mglkg) and
fentanyl (O.OOI-O.056 mglkg) showed anti-nociceptive effects in dose-dependent manners
(Fig. 1). All three opioids exhibited potent anti-nociceptive effect, and the highest doses
caused 1OOO/o MPE. The maximal effect was observed at approximately 15-30 min after each
opioid treatment (Fig. 1), and the ED50 values of anti-nociceptive effect measured at 15 min
after drug administration, were O.46 mglkg (oxycodone), 2.74 mglkg (morphine), and O.O086
mglkg (fentanyl), respectively (Table 2).
Constipation effects of oxycodone, morphine and fentanyl
      I evaluated the constipation effect ofoxycodone, morphine and fentanyl using the
castor oil-induced diarrhea model. This model is commonly used to evaluate the
opioid-induced constipation 48). First, I examined an appropriate timing to evaluate the
diarrhea after the castor oil administration and found that the maximum diarrhea response was
observed at 75 min after the administration (data not shown). Using this timing, I then
optimized an administration timing (5, 15, 30 min after the castor oil administration) of the
respective opioid to evaluate the anti-constipation effect (Fig. 2A). In all three opioids, the
maximum effects ofthe treatment were observed when the opioids were administered at 15
min after castor oil administration (Fig. 2B, 2C, 2D), and therefore, the dose-response effects
were examined by using this experimental protocol. Oxycodone (O.1-1 mglkg), morphine
(O. 17-1 mglkg) and fentanyl (O.O03-O.O17 mglkg) inhibited the castor oil-induced diarrhea in
dose-dependent manners, and the highest dose of each opioid completely inhibited the
diarrhea (Fig. 2E, 2F or 2G). The ED50 values for the constipation induced by oxycodone,
morphine and fentanyl were O.34 mglkg, O.40 mglkg, and O.O1 mglkg, respectively (Table 2).
Effects on behavioral inhibition by oxycodone, morphine and fentanyl
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      Since the maximum effects ofoxycodone, morphine and fentanyl in anti-nociception
were observed at approximately 15 min after the administration, the effects on behavioral
activity and respiration were also measured at the timing including (or around) 15 min after
the opioid administrations. I evaluated the effects ofoxycodone, morphine and fentanyl on
behavioral inhibition in rats during the 10-20 min after administration. Oxycodone (O.56-10
mglkg), morphine (1.7-30 mglkg) and fentanyl (O.O03-O.056 mg/kg) inhibited the total
activity counts in dose-dependent manners (Fig. 3A, 3B or 3C). I also noticed that the three
opioids induced muscular rigidity of limbs at higher doses by visual observation. The
behavioral inhibition induced by oxycodone, morphine and fentanyl were calculated as O/o
MPE, and the ED50 values for this pharmacological effects by oxycodone, morphine and
fentanyl were 1.02 mglkg, 7.49 mg/kg, and O.OO1 1 mglkg, respectively (Table 2).
Effects on the respiratory response by oxycodone, morphine and fentanyl
      To assess the effect of oxycodone (1 O-70 mglkg), morphine (10-70 mglkg) and
fentanyl (O.056-1 mg!kg) on respiration, I used whole-body plethysmography. Figure 4 shows
the dose-response effects ofoxycodone, morphine and fentanyl on the MV calculated from
the RR and the TV. All three opioids decreased the MV (i.e., resulted in increased O/o MPE) in
dose-dependent manners (Fig. 4). The oxycodone and morphine treatments inhibited the
respiratory response to 20-300/o ofMPE, whereas fentanyl inhibited the respiratory response
up to approximately 700/o of MPE. The higher doses were not employed in further experiment
since the opioid treatments around the highest doses used in the present study occasionally
resulted in fatal incidents. The ED50 values for the respiratory inhibition induced by
oxycodone, morphine and fentanyl were 170.3 mglkg, 4281 mg!kg, and O.45 mglkg,
respectively (Table 2).
      In all three opioids, the effects on RR compared with that in the saline treated group
were not significant (data not shown). On the other hand, oxycodone at doses of 56-70 mglkg,
morphine at doses of30-70 mglkg and fentanyl at doses ofO.3-1 mglkg significantly reduced
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the TV in dose-dependent manners (data not shown).
Development and validation of analytical methods for plasma concentrations of
oxycodone, morphine and fentanyl
      To understand relationships between the respective pharmacological effects and
plasma concentrations of opioids, I determined plasma levels of oxycodone, morphine and
fentanyl after subcutaneous administration. The plasma concentrations ofvarious opioids
have been determined using immunoassays, high-performance liquid chromatography
coupled with fluorescence, and gas chromatography-mass spectrometry. Above all, the liquid
chromatography-tandem mass spectrometry (LC-MSIMS) offers rapid and sensitive analysis
of opioids. Therefore, I used LC-MS/MS to measure the plasma concentrations of oxycodone,
morphine and fentanyl after subcutaneous administration. As the simultaneous determination
of the effects of different opioids has rarely been described previously, I developed and
validated a simple assay for the simultaneous determination of effects of three opioids using
multi-mode columns. The following parameters were determined for the validation ofthe
method for analyzing oxycodone, morphine and fentanyl in rat plasma: selectivity, linearity,
lower limit of quantification (LLOQ), precision, accuracy, and stability. Results ofthis
analysis are shown in Tables 3 and 4. The selectivity ofthe method was tested by comparing
the chromatogram of the pooled blank plasma with that of the pooled plasma spiked by the
opioids. All blank plasma was found to be free of interferences with respect in each MRM
scan mode. A line (y = ax + b) was fitted through the standard curve defined by a weighted
linear regression (weight = 11y2) ofthe peak area ratio ofIS (y) versus the actual
concentration ofthe analyte (x). LLOQ, defined in the presented study is the lowest plasma
concentration in the calibration curve that can be measured by precision and accuracy. The
precision and accuracy ofthe method were evaluated by the relative standard deviation (RSD)
and bias, respectively. The acceptable value ofRSD and bias were below 150/o and within
Å}200/o, respectively, and the analysis met these criteria. The stability of these compounds in rat
22
plasma was assessed with blank plasma prepared at low and high concentrations. These
samples were kept under different storage conditions and were expressed as residual ratio (O/o)
with respect to nominal concentration. The results, as shown in Table 4, demonstrated a good
stability ofmorphine during all tested storage conditions and confirmed the applicability of
the method for routine analysis. The assay was used for the analysis of rat plasma samples of
injected opioids, and no interferences or other problems were observed in the analyses of
these samples.
Plasma concentrations of oxycodone, morphine, and fentanyl
      As the plasma levels ofall three opioids were found to be the highest at 15 min after
the administration compared with the values at 5 and 60 min after the administration (data not
shown), I used the data obtained at 15 min for the analyses ofED50 and plasma
concentration-response curves. The subcutaneous administration ofoxycodone (O.3-10
mg/kg), morphine (O.3-30 mg/kg), or fentanyl (O.O1-1 mgtkg) produced dose-dependent
increases in the plasma concentrations (Fig. 5). The linear relationships between doses and the
plasma concentrations were observed over the dose ranges used in the present study
(regression equation and a square ofthe correlation coefficient (R2): oxycodone: y =
g7.6s6xi'0252, R2 = o.g3o3; morphine: y == 84.393xO'96i6, R2 = O.9616; fentanyl injection: y ==
4ss.41xi'28i9, R2 = O.9398; fentanyl citrate: y = 220.38xO`9049, R2 = O.8667) (Fig. 5). Figure 6
shows the plasma concentration-response curve for the respective pharmacological effects in
each opioid. The EC50 values ofplasma concentration for the anti-nociceptive effect and for
the adverse effects induced by oxycodone, morphine, and fentanyl are summarized in Table 2.
The data showed that fentanyl was the most potent drug with respect to all of the
pharmacological effects examined.
Relative efficacy of different pharmacological effects of oxycodone, morphine and
fentanyl
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      Figure 7 represents the relative efficacy of anti-nociceptive effect and adverse effects
(constipation, behavioral inhibition, and respiratory inhibition) in oxycodone, morphine and
fentanyl. In this figure, the EC50 values ofplasma concentration for constipation, behavioral
inhibition, and respiratory inhibition (Table 2) were divided by the EC50 value for the
anti-nociceptive effect (Table 2), and relative efficacy compared at the plasma concentration
(defined as a shift ratio) was determined in each opioid. The shift ratio represents the relative
margin in the plasma concentrations for each adverse effect over the concentration for the
anti-nociceptive effect.
      In all three opioids, the relative efficacies ofthe respective pharmacological effects
were essentially the same. Constipation orland anti-nociceptive effect resulted from a lower
plasma concentration range. Behavioral inhibition was induced at somewhat higher plasma
levels, followed by respiratory inhibition at much higher plasma levels. This result is
consistent with widely accepted classical opioid pharmacology. On the other hand, the relative
margins for each pharmacological effect differed among the opioids. In a comparison ofthe
shift ratio for constipation, oxycodone showed a relatively narrow margin (a shift ratio of
O.76) between the anti-nociceptive effect and the constipation effect, indicating that these two
pharmacological effects were induced at similar plasma concentrations. On the other hand, in
morphine, the shift ratio for constipation was O.1 1, indicating that the EC50 value for
constipation was nine times lower than that for the anti-nociceptive effect. As for fentanyl, the
potency to induce the constipation response was slightly weaker than that for the
anti-nociceptive effect (a shift ratio of 1.44). The shift ratios for behavioral inhibition against
the anti-nociceptive effect were 2.1O (oxycodone), 2.71 (morphine) and 1.32 (fentanyl). The
shift-ratio for the respiratory inhibition also differed among the opioids. Whereas the
oxycodone and morphine treatments showed relatively wider margins between the respiratory
inhibition and the anti-nociceptive effect (shift ratios of 244.79 and 233.13, respectively), the
margin was relatively narrower in the fentanyl treatment (a shift ratio of 104.21 ) (Fig. 7 and
Table 2).
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      Thus, oxycodone, morphine and fentanyl possessed unique pharmacological profiles
in terms of expression of different pharmacological effects, although all of these opioids are
known as agonists for the MORs.
Pharmacokinetics / pharmacodynamics (PKIPD) analyses of oxycodone, morphine and
fentanyl
      The previous study showed that equilibrium rates between peripheral and central
tissues affect the pharmacological profiles of opioid 39). I, therefore, performed PKIPD
analyses in the separate set of experiments. When I measured the time-course ofplasma and
brain concentrations of oxycodone (1 and 2 mg!kg, s.c.), morphine (3 and 6 mglkg, s.c.) and
fentanyl (O.03 and O.06 mgtkg, s.c.) in rats at 15, 30, 60, 120, and 180 min after
administration, the highest concentrations were observed at 15 min after the administration in
both plasma and brain in all opioids (Fig. 8). This result showed that oxycodone, morphine
and fentanyl exhibited parallel temporal changes between the plasma and brain levels, and
that centrallperipheral equilibrium is rapidly achieved in these opioids. However, each opioid
possessed distinct penetration rate from plasma to brain. The brain Kp value ofmorphine was
approximately O.5 at all timing tested, while those ofoxycodone and fentanyl were
approximately 2.5-3.0 (Fig. 8).
      I then analyzed the relationships between the anti-nociceptive effect as a
representative of central opioid action and the brain opioid concentrations in all three opioids.
In cases ofoxycodone and fentanyl, the linear relationships were observed between
concentrations and the anti-nociceptive effects over the dose ranges used in the present study
(Fig. 9), and preliminary modeling analysis showed that the concentration-effect relationships
appeared to fit the sigmoid Emax models (data not shown). On the other hand, such linear
relationship was not observed in the morphine treatment, and the time-course of
anti-nociceptive effect of morphine was delayed compared with the changes in the brain
concentrations (Fig. 9), showing the previously reported anti-clockwise hysteresis in the
25
concentration-effect relationship 39).
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Table 1 ; Analyte-dependent parameters of the MS detector
C"mpound Qlmi2 Q3mYz Tirae(mas) Parauaetexa
DP(V) EP(V) CE(V) CXP(wo
Morphine 2862 152.e 3eo 81 le 85 l6
Oxyendone 3i6.2 24e.9 3eg }3I 10 39 36
Fentanyl 33Z4 i88.l 3oe 161 IO 46 2e
IS 3oe.2 152.0 3oo 201 IO mp 32
DP: declusterikg petential; EP: entrance patential; CE: ce
CXP: collisiek eell exit potential.
liisien energsr;
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Table 2: The ECSO wtues ef the plasma concegtrations (ngrML) and the ED5e
values of the administered ctoses (mgacg) fer the dSfferent phamacelogical
effects ef oxycodoke, rnerphine ana fentanyl im rats.
Ceftstipation Anti-
neciception
Behavioral
imhibitien
Raspiratory
inhibitien
uinme
cma
titmpthitl;)
Doee
cltpte
zame,"gt
coerua
{irapmm
boee
{itv,etlrd
ha,m
corma
limpmÅr
!)oee
6Fni;Eigi)
Hsu,a
cma{ivtpteEl)
Do.e
Qrnetke)
Oxpeeaeltc 3467 g32 4757 eA6 99S2 M2 lllss l7g3
MerE!liime 2553 o3e 229.l 2S4 6212 7A9 5341g 42Sl
Fentanyl lA7 OSII lS2 ooes6 135 eml 1063 OAS
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Tab le 3 Validatien Gata fer the qnantification ef morphine, oxprcod one and fentanyl in ratplasma
n Merphine Cxycedone Fentanyl
Selectivity
-
Neinterference
Lirrtitedof
quantification
(LLO(?,ng/rnL)
.
20.0 2.oe e.soo
Qilantification
range
(ngfmL)
2 2o.e-loooo 2.00-IOOO e.soe-}ooe
Linearity
(7point,bias,efo) 2 - 6.2-"f5.2 - 7.6-+l2.l - 5.5--K;A - 7.0-+12.0
lhter-Gay
acguracy
(3peint,bias,e/")
5
-
5.6--1.5
-
5.4-+7.9
-
1.8-+5D - 10.4-+8.
e
imter-day
precision
(3peint,RSD,e/e)
5 O.3-5.1 e.6-2.3 e5-52 OS-7.0
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Table 4 Stability data of morphine, oxyeodene andi fentanyl in rat plasma
n
Merphine Oxyeadone Fentanyl
Cencentratien
(ngfmL) 6e,sooe 6o,seeo 6,8oo
Alltesampler
(2pGint,24hre/o) 3 93.6-lg2.9 S2.2-lll.O 88.4-le4.2
Reemtemaperature
(2peint,4hr,"/o) 3 91.3-96.7 95.2-I08,9 98.3-I03.8
Freezer
(2peint,32day,-
4o"c,o/e)
3 91.8-101S 93.1-lilD 97.e-U8.6
Freexeartdthaw
epeint,2times,-
4e"c,e/.)
3 91.8-IC3.8 98.4-108.9 97.4-le72
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                               Figure legends
Fig. 1: Time course ofanti-nociceptive effect induced by oxycodone, morphine, and fentanyl
following the subcutaneous administration in the rat tail-flick test. The anti-nociceptive effects
ofoxycodone (A), morphine (B), and fentanyl (C) were evaluated by the tail-fiick test. The
anti-nociceptive effect was expressed as O/o MPE. Data represent the mean Å} S.E.M. of 6-8
rats. "p Åq O.05, ""p Åq O.Ol or """p Åq O.OOI vs. saline group (two-way ANOVA, Dunnett's
multiple comparison test).
Fig. 2: Constipation effects ofoxycodone, morphine, and fentanyl evaluated by the castor
oil-induced diarrhea model. Experimental protocols of anti-diarrhea response induced by
opioid are shown in (A). Anti-diarrhea response was evaluated at 75 min after the castor oil
administration. in the time-course experiments, oxycodone (O.56 mglkg) (B), morphine (O.56
mglkg) (C) and fentanyl (O.O1 mglkg) (D) were subcutaneously administered at 5, 15, or 30
min after the castor oil treatment, and the constipation response was examined. In the
dose-response experiments, the constipation effects of oxycodone (O.1-1 mg!kg) (E),
morphine (O.I7-1 mglkg) (F), and fentanyl (O.O03-O.O17 mglkg) (G) were evaluated by
administration at 15 min after the castor oil treatment because this protocol provided the
maximum constipation effects in all opioids. Each column represents the mean Å} S.E.M. of6
rats. "p Åq O.05 or """p Åq O.OO1 vs. the saline group (two-way ANOVA, Dunnett's multiple
comparison test).
Fig. 3: Effects of oxycodone, morphine, and fentanyl on locomotor activity in the rats. Total
activity counts for each rat were measured during 1O-20 min after the subcutaneous
administration ofoxycodone (O.56-1O mglkg) (A), morphine (1.7-30 mglkg) (B), and
fentanyl (O.O03-O.056 mg/kg) (C). Each column represents the mean oflocomotor activity
counts during 1O-20 min after the drug treatment (mean Å} S.E.M. of 12-16 rats). "pÅqO.05,
"" p Åq O.Ol and """p Åq O.OO1 vs. saline group (two-way ANOVA, Dunnett's multiple
comparison test).
Fig. 4: Effects on respiratory response induced by oxycodone, morphine, and fentanyl in rats.
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Minute volume (MV) was obtained by using whole-body plethysmography at approximately
15 min after the administration of oxycodone (1O-70 mglkg) (A), morphine (1O-70 mgtkg)
(B), and fentanyl (O.056-1 mgA(g) (C). All values are expressed as ratios to baseline values
measured before opioid administration and shown as mean Å} S.E.M. of 7-1O rats. "p Åq O.05,
"" p Åq O.Ol or **"p Åq O.OOI vs. saline group (two-way ANOVA, Dunnett's multiple
comparison test).
Fig. 5: Linear relationships between subcutaneously administered doses and plasma
concentrations of oxycodone, morphine, and fentanyl in rats. The plasma concentration levels
ofoxycodone (O.3-10 mg!kg), morphine (O.3-30 mglkg), and fentanyl (Fentanest: O.O1-O.1
mgtkg or fentanyl citrate: O.1-1 mglkg) at 15 min after subcutaneous administration were
examined in rats. Each dot represents the plasma concentration ofthe individual rat. Three
rats were used in each dose group.
Fig. 6: Plasma concentration-response curves for the different pharmacological effects
induced by oxycodone, morphine, and fentanyl. The relationships between plasma
concentrations and the pharmacological effects induced by the subcutaneous administration of
oxycodone (A), morphine (B), and fentanyl (C) are shown. The pharmacological effects (-:
constipation, A: anti-nociception, V: behavioral inhibition, A: respiratory inhibition) are
expressed as O/o MPE. Each point represents the mean Å} S.E.M of 6-16 rats.
Fig. 7: Relative effricacy of different pharmacological effects in oxycodone, morphine, and
fentanyl in the rats (Pharmacological effect ladder). The EC50 values ofplasma concentration
for constipation, behavioral inhibition, and respiratory inhibition were divided by that for the
anti-nociceptive effect, and the relative efficacies of these adverse effects against the
anti-nociceptive effect were obtained (defined as shift ratios) in oxycodone (A), morphine (B),
and fentanyl (C). The y-axis represents the shift ratio, and the EC50 value ofplasma
concentration for anti-nociceptive effect was defined as 1.0 in each opioid.
Fig. 8: Time course ofchanges in plasma and brain concentrations ofoxycodone, morphine,
and fentanyl after the subcutaneous administration. The plasma and brain concentrations of
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oxycodone (1 mglkg) (A), morphine (3 mglkg) (B), and fentanyl (O.03 mglkg) (C) were
evaluated at 15, 30, 60, 120 and 180 (morphine only) min after the subcutaneous
administrations. The y-axis in each graph represents the concentration ofplasma (ng!mL) or
brain (nglg) . Qualitatively similar results were obtained by subcutaneous administrations of
oxycodone (2 mglkg), morphine (6 mglkg), and fentanyl (O.06 mg!kg) (data not shown). The
brain Kp values were calculated at respective time points in each opioids (D). Data
represent the mean Å} S.E.M. of3 rats.
Fig. 9: The relationships between brain concentrations and the anti-nociceptive effects of
oxycodone, morphine, and fentanyl. Oxycodone (1 and 2 mglkg) (A), morphine (3 and 6
mglkg) (B), and fentanyl (O.03 and O.06 mglkg) (C) were subcutaneously administered in rats,
and the anti-nociceptive effect and the brain opioid concentrations were measured. For the
PK experiment, separate animals were used from those for the pharmacological experiments.
The x-axis in each graph represents the brain concentrations ofoxycodone (1 and 2 mglkg)
(A), morphine (3 and 6 mg!kg) (B), or fentanyl (O.03 and O.06 mg!kg) (C) determined at 15,
30, 60, 120 and 180 (morphine only) min after the subcutaneous administrations, and the
y-axis represents the anti-nociceptive effect expressed as percentages ofthe maximal possible
effect (O/o MPE) induced by respective opioid treatments at the corresponding timings. Each
point represents the mean Å} S.E.M of 6 rats.
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Discussion
      I investigated the relationships between plasma concentrations ofthree opioid agonists
required for anti-nociceptive effect and the concentrations that induce various adverse effects
under controlled experimental setting. All three opioids resulted in an anti-nociceptive effect,
constipation, behavioral inhibition, and respiratory inhibition in a concentration-dependent
manner, and each opioid possessed distinct margins between the anti-nociceptive effect and
the respective adverse effects. Oxycodone and fentanyl induced both anti-nociceptive effect
and constipation at a similar plasma concentration level, whereas morphine induced
constipation at an approximately 9-fold lower concentration than that for the anti-nociceptive
effect. I also found that the margin between the effective plasma concentration for respiratory
inhibition and that for anti-nociceptive effect was relatively narrower in fentanyl among the
three opioids. Thus, oxycodone, morphine and fentanyl exhibited unique pharmacological
profiles, resulting in different ladder shapes ofvarious pharmacological effects (Fig. 7), even
under controlled experimental condition.
      In the present study, I employed the assays using LC-MSIMS to determine plasma
concentrations of each opioid, and the pharmacological effects were compared based on the
plasma concentration levels. I found that the individual variable ofplasma level was small
within the same dose group, and that the linear relationships were maintained between the
administered doses and the plasma concentrations within the dose ranges used in this study.
The plasma concentrations after the subcutaneous administration of oxycodone at 1 mglkg
and morphine at 1 mg/kg in rats were 100 nglmL and 80 nglmL, respectively. Although it is
difficult to speculate whether the opioid doses used in the present study are clinically relevant,
those used here are similar to the reported human plasma concentrations after oral
administration of oxycodone and morphine to relieve pain 52' 87).
      Several clinical reports showed that adverse effect profiles are not the same in
morphine, oxycodone and fentanyl. However, it is not clear whether such different profiles are
resulted from intrinsic pharmacological action ofeach opioid agonist or from variability in the
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clinical setting such as differences in administration route or patient background and
condition. In the present study, efficacy profiles of oxycodone, morphine and fentanyl were
compared not only by the same administration route and in the same rat strain, but also at
equianalgesic plasma concentrations. If these three opioid agonists exhibited their
pharmacological effects via same MOR function, one can predict that ladder shapes ofthe
various pharmacological effects would be the same when the effects were normalized by
equianalgesic plasma concentrations, whereas the effective plasma concentrations can be
different among the opioids. When I analyzed the effricacy of each opioid with respect to
plasma concentrations under controlled condition, unique profiles were observed in terms of
relations among plasma concentrations required for different pharmacological effects in each
opioid. Figure 6 and Figure 7 clearly showed that morphine, oxycodone and fentanyl
possessed different pharmacological profiles between the anti-nociceptive effect and the
respective adverse effects, suggesting that there are differences in mechanisms ofaction
among these p-opioid receptor agonists.
      Although the underlying mechanisms for the observed differences in the
pharmacological profiles of oxycodone, morphine and fentanyl are currently unknown, there
are several possibilities. 1) First, each opioid agonist affected to distinct mechanism in
addition to activation ofMOR to exhibit the pharmacological effects. However, oxycodone,
morphine and fentanyl are selective MOR agonists showing specific binding to MoRs 36• 37• 55).
In addition, the previous reports using morphine showed that the pharmacological effects
observed in the present study are thought to be resulted primarily from the activation of
MORs 83). It is unlikely, therefore, that mechanism other than MOR is responsible for the
different pharmacological profiles among these opioids. 2) Second, the responsible tissues
that express MOR are different for respective pharmacological effects, and differences in the
tissue distribution patterns among the opioids accounted for the observed differences.
Constipation may be explained by the relative importance ofperipheral and central activation
ofMORs since activation ofperipheral MOR is suggested to play a major role in inducing
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constipation 23). However, anti-nociception, behavior inhibition and respiration are primarily
mediated by opioid receptors located in the several CNS regions 42). Since my preliminary
data in mice showed that the relative distributions to different CNS regions were similar
among the opioids (Nakamura, in preparation), differences in tissue distribution of the opioids
is not likely to account for the unique ladder shape in the central pharmacological effects. 3)
The third possibility is that oxycodone, morphine and fentanyl possess distinct intrinsic
characters as MOR agonist and are differently activating the MOR system. For example, each
opioid may activate the MOR signaling machinery in a qualitatively or quantitatively different
manner, and the observed difference may be resulted from such agonist-dependent activation
of different intracellular mechanisms. Another possible mechanism is that different splice
variants ofMORs or dimmerization of opioid receptors are responsible for different
pharmacological effects ofeach opioid. Since recent studies suggested that the effect of
G-protein coupled receptor agonist can be regulated by such modifications at the receptor
levels in an agonist-dependent manner i5' i8' 26' 46' 7i), it is likely that the observed differences
in the pharmacological profiles are due to distinct intrinsic activity among those p-opioid
receptor agonists. The differences in the intrinsic activity among oxycodone, morphine and
fentanyl appear to be, at least in part, responsible for the different adverse effect profiles of
the opioids observed in the clinical setting.
      The previous study showed that differences in equilibrium rates between peripheral
and central tissues were observed among opioids, and that such pharmacokinetic differences
affected pharmacological profiles 39). Therefore, the different margins between the effective
plasma concentrations for constipation and that for anti-nociception among three opioids in
the present study might be due to such different equilibrium rates. ln the PKIPD analyses, I
found that the time-course of anti-nociceptive effect of morphine was delayed compared with
the changes in the plasma and brain concentrations, showing an anti•-clockwise hysteresis in
the concentration-effect relationship. In cases ofoxycodone and fentanyl such delay was not
observed. These data were consistent with the previous report using the clinical data 39).
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However, when I analyzed time-course ofchanges in both plasma and brain levels in each
opioid at different timings after subcutaneous administration, each opioid exhibited parallel
temporal changes between the plasma and brain levels. This suggests that centrallperipheral
equilibrium is rapidly achieved in these opioids and does not account for the different margin
between constipation and analgesic effects among opioids. On the other hand, I found that the
brain Kp value ofmorphine (Kp=O.5) was lower than those ofoxycodone (Kp=2.5-3.0) and
fentanyl (Kp==2.5). These data suggest that the lower brain penetration is at least one ofthe
reasons for the wider margin between the constipation effect and the anti-nociceptive effect in
morphine.
      In conclusion, I showed that oxycodone, morphine and fentanyl intrinsically possess
unique relative efficacy for different pharmacological effects. It is, therefore, important to
understand respective pharmacological profiles ofthose opioids for the appropriate use.
Although the margins among anti-nociceptive effect and respective pharmacological effects
observed in the present study do not directly represent the margins in a clinical setting, these
results provide an important suggestion in the clinical opioid use to control pain and adverse
effects.
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                             Chapter 2
   Comparative pharmacological profiles of morphine and oxycodone under a
neuropathic pain-like state in mice: evidence for less sensitivity to morphine
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                                   Introduction
      Neuropathic pain can elicit abnormal pain characterized in part by hyperalgesia, so
that noxious stimuli are perceived as more painfu1, and allodynia. Neuropathic pain is
particularly difficult to treat clinically, since it is only panially relieved by high doses of
morphine. Many studies have focused on the long-term changes in the functions of the spinal
cord dorsal hom neurons, which include some receptors, protein kinases and peptides,
following nerve injury 44' 62' 63). However, the mechanism of the reduced sensitivity to
morphine-induced antinociceptive effect under a neuropathic pain is not fu11y understood.
      Oxycodone, which is a semi-synthetic opioid analgesic derived from the naturally
occurring alkaloid, thebain, has good oral bioavailability and seems to provide analgesic
action that is as potent as that ofmorphine. It has been demonstrated that both oxycodone and
its active metabolite showed MOR agonistic activities 36). Several clinical studies have
suggested that oxycodone may be usefu1 for the treatment ofneuropathic pain 80' 96). Although
oxycodone has been clinically used for many years, its pharmacological properties are still
very poorly characterized.
      A growing body ofclinical evidence suggests that when opioid analgesics including
morphine are used to control pain in patients, psychological dependence is not a major
concern. It has been reported that morphine failed to induce rewarding effects in rats that had
been injected with formalin or carrageenan into the hind paw 57' 89-9i). Furthermore, it has been
documented that chronic pain attenuates the development oftolerance to the antinociceptive
effect of morphine in rats 94). These findings suggest the possibility that pain could lead to
physiological changes at supraspinal levels associated with the suppression of opioid
dependence.
      The aim of the present study was to further compare pharmacological profiles of
morphine and oxycodone following sciatic nerve ligation and investigate the mechanisms
underlying less sensitivity to morphine under a neuropathic pain-like state.
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Materials and Methods
Animals
      Male ICR mice (20-25 g) and male guinea pig (250-300 g) (Tokyo Laboratory
Animals Science Co., Ltd, Tokyo, Japan) were used in the present study. Animals were
housed in a room maintained at 22Å}10C with a 12 hr light-dark cycle. Food and water were
available ad libitum. Each animal was used only once.
Receptor binding assay
      For membrane preparation, the mouse brain without cerebellum and the guinea pig
cerebellum were quickly removed after decapitation, and rapidly transferred to a tube fi11ed
with an ice-cold buffer. The homogenate was centrifuged at 40C for 10 min at 1,OOOxg and the
surpernatant was centrifuged at 40C for 20 min at 48,OOO Å~ g. The pellet was resuspended at
40C for 20 min at 48,OOO Å~ g. The resulting pellet was resuspended and retained as membrane
fraction. The MOR, DOR and KOR binding assays were performed in duplicate with
[tylosil-3,5-(3)H(N)]-[D-Ala(2),N-MePhe(4),Gly-ol(5)]enkephalin ([3H] DAMGO) (specific
activity, 59.0 Cilmmol; Amersham Biosciences, Arlington Heights, IL) at 1 nM,
(2-D-penicillamine, 5-D-penicillamine)-enkephalin ([3H] DPDPE) (specific activity, 45.0
Cilmmol; PerkinElmer Life science, Arlington Heights, IL) at 2 nM or
[phenyl-3,4-(3)H]-(5ct,7ct,8B)-3,4-N-Methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4,5]dec-8-yl]-b
enzeneacetamide ([3H] U69,593) (specific activity, 41.7 Cilmmol; PerkinElmer Life science,
Arlington Heights, IL) at 2 nM in a final volume of 1.0 ml that contained 50 mM Tris-HCI
buffer, pH 7.4, and O.1 ml ofthe membrane fraction. The amount ofmembrane proteins used
in each assay was in the range of90-140 pg, as determined by the method ofNarita et al. 59).
The test tubes were incubated for 1 hr at 250C. Specific binding was defined as the difference
in bindings observed in the absence and presence of 1 pM unlabeled DAMGO, DPDPE or
U50,488. Incubation was terminated by collecting membranes on Whatman GFIB filters using
a Brandel cell harvester. The filters were then washed three times with 5 ml Tris-HCI buffer,
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pH 7.4, at 40C and transferred to scintillation vials. Then, 4 ml of clear-sol 2 (Nacalaitesque,
INC. Kyoto, Japan) was added to the vials. After a 12 hr equilibration period, radioactivity in
the samples was determined in a liquid scintillation analyzer.
Guanosine-5'-o-(3-thio) triphosphate ({35SIGTPyS) binding assay
      For membrane preparation, the mouse spinal cord, thalamus, periaqueductal gray
matter (PAG), a section ofthe lower midbrain that included the ventral tegmental area (VTA),
which described previously 70), and the guinea pig cerebellum were quickly removed after
decapitation, and rapidly transferred to a tube fi11ed with ice-cold buffer. The membrane
homogenate (3-8 pg proteinlassay) was prepared as described previously 70) and incubated at
250C for 2 hr in 1 ml ofassay buffer with various concentrations ofeach agonist, 30 ptM
guanosine-5'-diphosphate (GDP) and 50 pM [35S]GTPyS (specific activity, 1000 Cilmmol;
Amersham, Arlington Heights, IL, USA). The reaction was terminated by filtration using
Whatman GFIB glass filters (Brandel, Gaithersburg, MD, USA) that had been presoaked in 50
ptM Tris-HCI, pH 7.4, and 5 pM MgC12 at 40C for 2 hr. The filters were washed three times
with 5 ml ofice-cold Tris-HCI buffer, pH 7.4, and then transferred to scintillation-counting
vials containing O.5 ml ofSoluene-350 (Packard Instrument Co., Meriden, CT, USA) and 4 ml
ofHionic Fluor (Packard Instrument Co.) and equilibrated for 12 hr. The radioactivity in the
samples was determined with a liquid scintillation analyzer. Nonspecific binding was
measured in the presence of 10 ptM unlabeled GTPyS. In the present study, sample
preparation was performed 7 days after panial sciatic nerve-ligation.
Neuropathic pain model
      The mice were anesthetized with sodium pentobarbital (70 mglkg, i.p.) or 30/o
isoflurene. I produced a partial sciatic nerve injury by tying a tight ligature with a 8-O silk
suture around approximately one-halfthe diameter ofthe sciatic nerve on the right side
(ipsilateral side) under a light microscope (SD30, Olympus, Tokyo,Japan) as described
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previously 4i' 82). In sham-operated mice, the nerve was exposed without ligation. I previously
reported that the sciatic nerve-ligated mice exhibit the themial hyperalgesia and the
mechanical hyperalgesia on the ipsilateral side, indicating the state ofneuropathic pain
hypersensitivity. These persistent painfu1 states caused by sciatic nerve ligation lasted for
more than 15 days 6i).
Inflammatory pain model
      A persistent inflammatory pain model was produced by unilateral intraplantar
injection of complete Freund' s adjuvant (CFA; Mycobacterium tuberculosis; Sigma, St. Louis,
MO, USA) in 50 Al into the plantar surface ofthe right hind paw (ipsilateral side) ofmice
under the anesthesia with sodium pentobarbital (70 mg!kg, i.p.) or 30/o isoflurene 65). The
control mice were given saline into the plantar surface of the right hind paw.
Intrathecal (i.t.) injection
      I.t. administration was performed following the method described previously 25) using
a 25-pl Hamilton syringe with a 30-gauge needle. The injection volume was 4 pl for each
mouse. Each solution was injected without injection cannulae.
Intracerebroventricular (i.c.v.) injection
      I.c.v. administration was performed following the method described previously with
modifications i9' 56). To make a hole in the sku11 for injection, one day before the
administration ofeach drug, mice were briefly anesthetized with ether and a 2-mm
double-needle (tip: 27G Å~ 2 mm and base: 22G Å~ 10 mm, Natsume Seisakusyo Co. Ltd.,
Tokyo, Japan) attached to a 25-pl Hamilton microsyringe was inserted into a unilateral
injection site using a V-shaped holder to hold the head of the mouse. The unilateral injection
site was approximately 2 mm from either side of the midline between the anterior roots of the
ears. On the day of the tail-flick assay, the head of the mouse was held against a V-shaped
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holder and the drugs were injected into the hole. The injection volume was 4 pl for each
mouse. Each solution was injected without injection cannulae.
Measurement of thermal hyperalgesia
      To assess the sensitivity to thermal stimulation, each ofthe hind paws ofmice was
tested individually using a thermal stimulus apparatus (UGO-BASILE, Biological research
apparatus, VA, Italy). The intensity of the thermal stimulus was adjusted to achieve an
average baseline paw withdrawal latency of approximately 8 to 10 sec in naive mice. Only
quick hind paw movements (with or without licking ofthe hind paws) away from the stimulus
were considered to be a withdrawal response. Paw movements associated with locomotion or
weight shifting were not counted as a response. The paws were measured alternating between
the left and right with an interval ofmore than 3 min between measurements. The latency of
paw withdrawal after the thermal stimulus was determined as the average ofthree
measurements per paw.
Assessment of anti-nociception
      Anti-nociception induced by oxycodone or morphine was determined by the tail-flick
test (Tail Flick Analgesia Meter Model MK 330B, Muromachi Kikai Co. Ltd., Tokyo, Japan).
The intensity ofthe heat stimulus was adjusted so that the animal flicked its tail after 3-5 s.
When the intensity of stimulation was enough to produce a basal movement within 3-5 s in
mice, it was defined that pharmacological observation results from the spinal reflex and
supraspinal modulations 34). The inhibition of this tail-fiick response was expressed as a
percentage of the maximum possible effect (MPE), which was calculated as ((Ti -
To)Å~1OOI(T2 - To)), where To and Ti were the tail-flick latencies before and after the
administration ofeach MOR agonist and T2 was the cut-offtime (set at 1O s) in the tests to
avoid injury to the tail. In the present study, the antinociceptive assay was performed 7 days
after partial sciatic nerve-ligation. Each group consisted of 8-1 1 mice.
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Place conditioning
      Place conditioning studies were conducted using a shuttle box (15 Å~ 30 Å~ 15 cm, w Å~ 1
Å~ h) that was made ofan acrylic resin board and divided into two equal-sized compartments.
One compartment was white with a textured floor and the other was black with a smooth floor
to create equally inviting compartments. The place conditioning schedule consisted of three
phases (pre-conditioning test, conditioning and post-conditioning test). The pre-conditioning
test was performed as follows: the partition separating the two compartments was raised to 7
cm above the floor, a neutral platform was inserted along the seam separating the
compartments, and mice that had not been treated with either drugs or saline were then placed
on the platform. The time spent in each compartment during a 900-s session was then
recorded automatically using an infrared beam sensor (KN-80, Natsume Seisakusyo Co., Ltd.,
Tokyo, Japan). Immediately after s.c. injection of morphine (3-1O mglkg) or oxycodone (O.3-3
mglkg), these animals were placed in the compartment opposite that in which they had spent
the most time in the pre-conditioning test for 1 hr. On alternate days, these animals received
vehicle and were placed in the other compartment for 1 hr. On the day after the final
conditioning session, a post-conditioning test that was identical to the pre-conditioning test
was performed.
Drugs
      The drugs used in the present study were morphine hydrochloride (Daiichi-Sankyo
Co., Tokyo, Japan), oxycodone hydrochloride (a kind gift from Shionogi Pharmaceutical Co.
Inc., Osaka, Japan), M-6-G (Sigma-Aldrich Co., St. Louis, MO, USA), [D-Ala2, N-Me-Phe`,
Gly5-ol] enkephalin (DAMGO; Sigma-Aldrich Co., St. Louis, MO, USA),
(+)-4-[(ctR)-ct-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-metyoxybenzyl]-N,N-diethylbe
nzamide] (SNC80; Tocris Cookson Ltd, Ballwin, MO, USA), (-)trans-(1S,2S)-U-50,488
(U50,488; Sigma-Aldrich Co., St. Louis, MO, USA), ICI 199,441 hydrochloride (Tocris
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Cookson Ltd., Ballwin, MO, USA), P-funaltrexamine hydrochloride (B-FNA), naltrindol
hydrochloride (NTI; Tocris Cookson Ltd., Ballwin, MO, USA) and nor-binaltrophimine
dihydrochloride (nor-BNI; Tocris Cookson Ltd., Ballwin, MO, USA). All drugs were
dissolved in O.90/o physiological saline (Otsuka Pharmaceutical Co. Inc., Tokyo, Japan) for in
vivo experiments or assay buffer for in vitro experiments.
Statistical analysis
      The data for antinociceptive response were shown as the mean Å} S.E.M. of O/o MPE.
The data for [35S]GTPyS binding assay were expressed as the mean Å} S.E.M. ofO/o
Stimulation. Receptor binding curves were fitted using the GraphPad Prism 4,O program.
The statistical significance of differences between the groups was assessed with a two-way
ANOVA followed by BonferronilDunn multiple comparison test or Student's t-test.
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                                  Results
Binding properties of oxycodone with opioid receptor
      To evaluate the specific involvement ofthe opioid receptor types in
oxycodone-induced pharmacological actions, I performed the competitive displacement
binding assay. At first, I determined the competitive displacement binding of the MOR ligand
[3H]DAMGO (Fig. IA), the DOR ligand [3H]DPDPE (Fig. IB) or the KOR ligand
[3H]U69,593 (Fig. 1C) with graded concentrations (1O-ii-1O-7 M) ofunlabeled opioid agonists
in membranes of the mouse brain without cerebellum (Fig. IA or B) and the guinea pig
cerebellum, which is relatively rich in KOR sites (Fig. 1C). As shown in table 1, ICso values
were determined by the djsplacement of [3H] DAMGO, [3H]DPDPE or [3H]U69,593 (Table
1). The [3H]DAMGO binding was clearly displaced by morphine or oxycodone in a
concentration-dependent manner. The affmity ofoxycodone to the MOR binding was about
10 times lower than that ofmorphine. In contrast, the binding ofeither [3H]DPDPE or
[3H]U69,593 was not affected by morphine or oxycodone, whereas [3H]DPDPE or
[3H]U69,593 binding was displaced by increasing concentrations ofeither a selective DOR
agonist SNC80 or a specific KOR agonist U50,488, respectively.
      I next investigated the ability of oxycodone to activate G-proteins in the mouse
thalamus, spinal cord and the guinea pig cerebellum membranes. Either morphine (10-8-10-5
M) or oxycodone (10-8-10-5 M) showed a concentration-dependent increase in the binding of
[35S]GTPyS to membranes ofthe mouse thalamus (Fig. 2A or 2C) and spinal cord (Fig. 3A or
3C). Co-incubation with a MOR antagonist P-FNA (1O'7 M) significantly attenuated ejther
morphine- or oxycodone-induced G-protein activation, whereas either a DOR antagonist NTI
(10'7 M) or a KOR antagonist nor-BNI (10-7 M) failed to affect those ofmorphine and
oxycodone ("**pÅqO.OOI P-FNA-morphine vs. morphine alone, ###pÅqO.OOI
P-FNA-oxycodone vs, oxycodone alone, Fig. 2B, 2D, 3B or 3D). Conventional KOR agonists,
U50,488 and ICI-199,441, (10-8-1O-5 M) produced a concentration-dependent increase in
[35S]GTPyS binding to membranes of the guinea pig cerebellum region (Fig. 4). In contrast,
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morphine (10'8-10-5 M) showed relatively smaller increase in the binding of [35S]GTPyS than
that of KOR agonists. Furthermore, a little change in the binding of [35S]GTPyS to
membranes ofthe guinea pig cerebellum region was noted by oxycodone (10-8-10-5 M) (Fig.
4).
      I next investigated the role ofMOR in oxycodone (3 mg!kg, s.c.)-induced
anti-nociception using the tail-flick assay. Pretreatment with P-FNA (40 mglkg, s.c.)
significantly attenuated the oxycodone-induced anti-nociception (Fig. 5A), whereas either
nor-BNI (5 mglkg, s.c.) or NTI (3 mglkg, s.c.) had no effect on the anti-nociception of
oxycodone ("""pÅqO.OOI vs. saline-pretreated group, Fig. 5B or 5C).
Effect ef s.c. injection of morphine or oxycodone on thermal hyperalgesia induced by
sciatic nerve ligation or intraplantar injection of CFA in mice
      Sciatic nerve-ligated mice produce the state ofneuropathic pain-like hypersensitivity.
The persistent painfu1 state caused by sciatic nerve ligation lasted for more than 21 days (data
not shown). In the present study, mice with partial sciatic nerve ligation exhibited marked
neuropathic pain-like behavior only ipsilateral side at 7 days after the nerve ligation
("""pÅqO.OO1 vs. sham-saline group ) (Fig. 6A or 6B). Unilateral intraplantar injection ofCFA
into the mouse hind paw produces the state of inflammatory pain-like hypersensitivity, which
caused a marked decrease in the latency ofpaw withdrawal against a thermal stimulus only on
the ipsilateral side in mice (""*pÅqO.OOI vs. saline-saline group) (Fig. 6C or 6D). The
persistent painfu1 state caused by intraplantar injection of CFA lasted for more than 14 days
following CFA treatment in mice (data not shown). The s.c. injection ofeither morphine (1-10
mgfkg) or oxycodone (O.1-3 mgfkg) 7 days after sciatic nerve ligation or 1 day after CFA
treatment recovered the decreased thermal threshold observed on the ipsilateral side in sciatic
nerve-ligated or CFA-treated mice in a dose-dependent manner, and maximal
anti-hyperalgesic responses were seen at 30 or 15 min after morphine or oxycodone injection,
respectively (ligation-morphine 1 mgtkg, *""pÅqO.OOI; ligation-morphine 3 mglkg, ""pÅqO.Ol
56
vs. sham-saline group: Fig. 6A, ligation-oxycodone O.1 or 1 mglkg, "*pÅqO.Ol;
ligation-oxycodone 3 mg/kg, "*"pÅqO.OOI vs. sham-saline group: Fig. 6B, CFA-morphine 1, 5
or 10 mglkg, """pÅqO.OOI vs. saline-saline group: Fig. 6C, CFA-oxycodone O.1 or 3 mglkg,
""* pÅqO.OOI; CFA-oxycodone 1 mglkg, ""pÅqO.Ol vs. saline-saline group: Fig. 6D). At the
dose of5 mglkg or O.5 mglkg, s.c. administration ofmorphine or oxycodone, respectively,
almost completely reversed the decrease in the thermal threshold without excessive effects in
sciatic nerve-ligated mice. In contrast, either 3 mgtkg (s.c.) ofmorphine or O.5 mglkg (s.c.) of
oxycodone reversed the decreased thermal threshold in CFA-treated mice.
Characterization of the anti-nociception induced by morphine or oxycodone under a
neuropathic-pain like state
      I evaluated the antinociceptive effects induced by s.c. administration ofmorphine or
oxycodone in sham-operated and sciatic nerve-ligated mice using the tail-fiick assay. In the
present study, s.c. administration of either morphine or oxycodone produced a dose-dependent
antinociceptive effect in sham-operated mice, and maximal antinociceptive responses were
seen at 30 and 15 min after injection, respectively. The antinociceptive effect ofs.c.-injected
morphine was significantly decreased in sciatic nerve-ligated mice Åqligation-morphine 1.7
mgtkg, "pÅqO.05; ligation-morphine 3 or 5.6 mglkg, *"pÅqO.O1; ligation-morphine 10 mgtkg,
""" pÅqO.OOI vs. sham-morphine group) (Fig. 7A). In contrast, s.c. injection ofoxycodone
produced profound anti-nociception in sciatic nerve-ligated mice at the same level as
observed in sham-operated mice (Fig. 7B).
      I next examined the antinociceptive effects induced by either i.t. or i.c.v.-administered
morphine or oxycodone in sham-operated and sciatic nerve-ligated mice. I.t. injected
morphine or oxycodone each had a dose-dependent antinociceptive effect in sham-operated
and sciatic nerve-ligated mice (Fig. 7C or 7D). The maximal antinociceptive effect of
i.t.-administered morphine or oxycodone was observed at 10 or 5 min, respectively, following
each injection (data not shown). I.c.v.-administered morphine and oxycodone each produced
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significant anti-nociception in sciatic nerve-ligated mice to the same level as observed in
sham-operated mice (Fig. 7E or 7F). The maximal antinociceptive effect ofi.c.v.-administered
morphine or oxycodone was observed 1O or 5 min, respectively, following each injection
(data not shown). As shown in table 2, the EDso values for the antinociceptive effects of
morphine and oxycodone following each injection in sham-operated or sciatic nerve-ligated
mice (Table 2).
Spinal and supraspinal G-protein activation induced by morphine or oxycodone in
nerve-ligated mice
      I next investigated the ability ofmorphine (Fig. 8A, 8C or 8E) or oxycodone (Fig. 8B,
8D or 8F) to activate G-proteins through the stimulation ofMORs in membranes ofthe mouse
spinal cord (Fig. 8A or 8B), PAG (Fig. 8C or 8D) and thalamus (Fig. 8E or 8F) obtained from
sham-operated and sciatic nerve-ligated mice. The activation ofG-proteins induced by
morphine or oxycodone (1O-8-1O-5 M) in these areas was examined by monitoring the binding
of [35S]GTPyS to membranes. Morphine and oxycodone each produced a
concentration-dependent increase in [35S]GTPyS binding to membranes of the mouse spinal
cord, PAG and thalamus in sham-operated mice (Fig. 8). In sciatic nerve-ligated mice, the
levels of [35S]GTPyS binding stimulated by morphine and oxycodone were similar to that
found in sham-operated mice (Fig. 8).
Suppression of the antinociceptive effect and G-protein activation induced by
morphine-6•-glucuronide (M-6-G) at spinal or supraspinal levels under a neuropathic
pain-like state
      In the mouse tail-fiick test, either s.c., i.t. or i.c.v. administration ofM-6-G induced
marked anti-nociception in sham-operated mice as with morphine and oxycodone (Fig. 9).
The antinociceptive effects induced by all three injections ofM-6-G were significantly
decreased in nerve-ligated mice compared to those in sham-operated mice (s.c.:
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ligation-M-6-G 1 or 5.6 mglkg "pÅqO.05; 1.7 or 3 mglkg "*"pÅqO.OOI vs. sham-M-6-G group;
i.t.: ligation-M-6-G O.Ol or O.03 nmollmouse **"pÅqO.OOI; O.056 or O.1 nmol/mouse *"pÅqO.OI
vs. sham-M-6-G group; i.c.v.: ligation-M-6-G O.03 nmollmouse "pÅqO.Ol; O.3 or O.56
nmollmouse """pÅqO.OOI vs. sham-M-6-G group) (Fig. 9A, 9B or 9C).
      I further investigated the changes in the ability ofM-6-G to activate G-proteins in
membranes ofthe spinal cord, PAG or thalamus obtained from sham-operated or sciatic
nerve-Iigated mice. The binding of [35S]GTPyS stimulated by M-6-G was significantly
decreased in nerve-ligated mice, whereas M-6-G (1O-8-1O-5 M) produced a
concentration-dependent increase in the binding of [35S]GTPyS to membranes of the spinal
cord and PAG area in sham-operated mice (spinal cord: F(i,42)=28.80, ""pÅqO.O1 vs.
Iigation-M-6-G group; PAG: F(i,36)=13.36, ""pÅqO.Ol vs. Iigation-M-6-G group) (Fig. 10A or
10B). On the other hand, M-6-G produced a concentration-dependent increase in [35S]GTPyS
binding to membranes of the mouse thalamus in sham-operated mice. In sciatic nerve-ligated
mice, the level of [35S]GTPyS binding stimulated by M-6-G in the TH was similar to that
found in sham-operated mice (Fig. 10C).
Inhibition of morphine- or oxycodone-induced place preference and G-protein activation
in the lower midbrain with sciatic nerve-ligated mice
      I next investigated whether morphine or oxycodone could produce rewarding effects
in sciatic nerve-ligated mice using the CPP method. As shown in Fig. 1 1, s.c.-administered
morphine and oxycodone each produced a dose-dependent preference for the drug-associated
place in sham-operated mice (sham-morphine 3 or 5.6 mglkg, sham-oxycodone 1 or 3 mgtkg,
##pÅqO.O1; sham-morphine 1O mglkg ###pÅqO.OOI vs. sham-saline group). In contrast, neither
morphine nor oxycodone induced a place preference under a neuropathic pain-like state
(ligation-morphine 5.6 or 10 mglkg "pÅqO.05; ligation-oxycodone 1 or 3 mglkg "pÅqO.05 vs.
sham-morphine or -oxycodone group) (Fig. 1IA or 1IB).
      I assessed the morphine- or oxycodone-induced increase in [35S]GTPyS binding in the
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lower midbrain including the VTA obtained from sham-operated or sciatic nerve-ligated mice
According to atlas described by Paxions and Franklin 74), the coronal brain block ofthe lower
midbrain area (box) was dissected obtained from 2.5 to 4.5 mm posterior to bregma (Fig.
11C). Morphine and oxycodone (1O-8-1O'5 M) each produced a concentration-dependent
increase in the binding of [35S]GTPyS to lower midbrain membranes in sham-operated mice.
Conversely, the level of [35S]GTPyS binding to this area stimulated by morphine or
oxycodone in nerve-ligated mice was significantly lower than that observed in sham-operated
mice (F(i,36)=13.43, *pÅqO.05 vs. Iigation-morphine group; F(i,36)=20.36, ##pÅqO.Ol vs.
Iigation-oxycodone group) (Fig. 1ID or 1IE).
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Table 1 Binding prGperty ef oxycedone for the IL-, ti- er x-epioid receptor
determed by displacemeMt ef PHIDAMoo, FH]DPD?E or PH]U69,593
ICso values were determined using the analysis efvariattce and liAea!r regression teehniques. Groups
vvere treated with merphine, oxyeodone, fentanyl, SNCgO or U50,48g. To ealuculate ICsfi values, at
least 7 drug dose$ were used and 3-4 samples were usee for eaeh dcse, Values in parenthesis
indieate the 950/e cenftdence range.
Morphine Oxycoclone SNCge use,4ss
[3H]DAIMGO(hlND 2.29Åq1.97-2.67)
20.26
(IS.02-27,32År
N,D. N.D.
[3H]DPDPE(kM) Åqsoo Åq500
S,l7
(3.90-6,84) N.D.
FH]U69,593(ttMÅr
161.3
(69.62-373,7)
Åq500 N,D. 1.16
(O.96-14,12)
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Tgble 2 EDsc vulues and shift-ratie of the grritineciceptive effeets of rnerphine,
exsco(}eke or M-6-G in sham-operadedi and scintic merve Mgr"tion.
EDso values were determined using the analysis ef variance and linear regression techniques. Te
caluculate EDse values, at least 6 drug doses were used and 6-11 mice were used fer eaeh dose.
Values in parenthesis indicate the 950/) confidence range. Tke shift-ratie was caluculated as
(ligation-group EDse value$Ysham-group Ebsa values). Groups ofmice were treated v{rith merphine,
oxycodone or M-6-G 7 days after the nerve iigation, *':EpÅqe.OOI vs. sham-group.
EP50Vabas Shift-rativ(ngatioulsimi)
sim Ligation
lrESectinttsite MerphSrve Oxyeodnme M-6.G Merpim Oxsrcodnrle M-6-G MorphineOxyeotli,zae M6.G
s.c.(rvtgS3gl
2.46
(2,08-2.92)
g,7
(O.59-083)
l,06
(e,89-i27)
6.S2+-
(4,818.83)
e.71
(O.64-O,8)
4.84-M
(3•72-tfu31) 2.65IBi 4.S?
i.t.(mmUineuse e,4I
(O.31-O.53)
6.2
(4SO-?.S4)
O.[M9
(e.CC}66-B,O12
O,44
(O,32-g.6i)
6,53
(5.33-8.{}O)
o.g4&e
(g.a3s-G.o62) IM71.g5 5.ll
'
.e,v,(maYrttmvas l.49
(123-1.80)
2.84
(2.3S3.44)
O,064
(b,B46-g.E}S9)
152
(2,21.l.9g)
3,15
(2,46-4.B4)
O,34"ti
(O.18-".63) ID21,ll 531
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                               Figure legends
Fig. 1: Displacement of the p-opioid receptor ligand [3H]DAMGO (A),6-opioid receptor
ligand [3H]DPDPE (B) or the K-opioid receptor ligand [3H]U69,593 (C) binding in
membranes ofthe mouse brain without cerebellum (A or B) and the guinea pig cerebellum
(C) by morphine, oxycodone, SNC80 or U50,488. Experiments were performed in the
presence ofeither [3H]DAMGO (1 nM), [3H]DPDPE (2 nM) or [3H]U69,593 (2 nM) and
increasing concentrations ofmorphine, oxycodone, SNC80 or U50,488. The data represent
the mean Å} S.E.M. of3-4 samples.
Fig. 2: Concentration response curve of [35S]GTPyS binding to membranes induced by
morphine (A) or oxycodone (C) in the mouse thalamus. Either morphine- (B) or oxycodone-
(D) induced increase in [35S]GTPyS binding to membranes of the mouse thalamus was
blocked by the selective p-opioid receptor antagonist P-FNA, but not the 5-opioid receptor
antagonist NTI or the K-opioid receptor nor-BNI. Membranes were incubated with
[35S]GTPyS and GDP with morphine or oxycodone in the presence or absence of B-FNA, NTI
or nor-BNI. The data are shown as the percentage ofbasal [35S]GTPyS binding measured in
the presence ofGDP and absence ofmorphine or oxycodone. Each column represents the
mean Å} S.E.M. of3-6 samples. *"*pÅqO.OOI P-FNA-morphine vs. morphine alone.
###pÅqO.OOI P-FNA-oxycodone vs. oxycodone alone.
Fig. 3: Concentration response curve of [35S]GTPyS binding to membranes induced by
morphine (A) or oxycodone (C) in the mouse spinal cord. Either morphine- (B) or
oxycodone- (D) induced increase in [35S]GTPyS binding to membranes of the mouse thalamus
was blocked by the selective p-opioid receptor antagonist P-FNA, but not the 6-opioid
receptor antagonist NTI or the K-opioid receptor nor-BNI. Membranes were incubated with
[3SS]GTPyS and GDP with morphine or oxycodone in the presence or absence of P-FNA, NTI
or nor-BNI. The data are shown as the percentage ofbasal [35S]GTPyS binding measured in
the presence ofGDP and absence ofmorphine or oxycodone. Each column represents the
mean Å} S.E.M. of4-6 samples. "**pÅqO.OOI P-FNA-morphine vs. morphine alone.
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###pÅqO.OOI P-FNA-oxycodone vs. oxycodone alone.
Fig. 4: Concentration response curve of [35S]GTPyS binding to membranes obtained from the
guinea pig cerebellum by U50,488, ICI-199,441, oxycodone or morphine. The columns are
expressed as the percentage ofbasal [35S]GTPyS binding. The data represent the mean Å}
S.E.M of4 samples.
Fig. 5: Effects ofpretreatment with p-opioid receptor antagonist P-FNA (A), 6•-opioid
receptor antagonist NTI (B) or K-opioid receptor antagonist nor-BNI (C) on s.c.
oxycodone-induced anti-nociception in mice. Anti-nociception was expressed as a
percentage ofmaximum possible effect (O/o MPE). Groups ofmice were pretreated with
P-FNA (40 mg!kg), NTI (3 mglkg) or nor-BNI (5 mglkg) at 24 hr, 30 min or 24 hr,
respectively, before s.c. administration of oxycodone (1 .7 mg!kg). Each point represents the
mean Å} S.E.M. of6-10 mice. *pÅqO.05 and """pÅqO.OOI vs. saline + oxycodone.
Fig. 6: Effect of s.c. injection ofmorphine (A or C) or oxycodone (B or D) on the latency of
paw withdrawal in response to thermal stimulus on the ipsilateral side in sham-operated and
sciatic nerve-ligated mice (A or B) or saline- or CFA-injected mice (C or D). Measurement of
thermal threshold was performedjust before and 3e or 15 min after s.c. injection ofmorphine
or oxycodone, respectively. Groups ofmice were treated with morphine (1-1O mglkg) or
oxycodone (O.1-3 mglkg) 7 days after sciatic nerve ligation or 1 day after CFA injection. Each
column represents the mean Å} S.E.M. of6-11 mice. "*"pÅqO.OOI and *"pÅqO.Ol vs.
sham-saline group or saline-saline group.
Fig. 7: Dose-response curves for the antinociceptive effect induced by s.c., i.t. or i.c.v.
morphine (A, C or E) or oxycodone (B, D or F) in sham-operated and sciatic nerve-ligated
mice. Groups ofmice were treated with morphine (O.56-30 mglkg, s.c., O.1-1.7 nmollmouse,
i.t. or O.3-5.6 nmollmouse, i.c.v.) or oxycodone (O.17-3 mglkg, s.c., 1-30 nmollmouse, i.t. or
O.56-1O nmol/mouse, i.c.v.) 7 days after nerve ligation. Antinociceptive effects were measured
at 30 or 15 min after s.c., 1O or 5 min after i.t. or 1O or 5 min after i.c.v. injection ofmorphine
or oxycodone as the peak time ofmorphine or oxycodone activity, respectively.
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Antinociceptive effects were measured the peak time after each injection of morphine or
oxycodone, respectively. Anti-nociception was expressed a$ a percentage of the maximum
possible effect (O/o MPE). Each value represents the mean Å} S.E.M. of8-10 mice.
"pÅqO.05,"*pÅqO.Ol and **"pÅqO.OOI vs. sham group.
Fig. 8: No difference was observed in the binding of [35S]GTPyS stimulated by morphine (A,
C or E) or oxycodone (B, D or F) in the spinal cord (A or B), the periaqueductal gray matter
(C or D) or thalamus (E or F) obtained from sham-operated and sciatic nerve-ligated mice.
Membranes were prepared at 7 days after nerve ligation. Each value represents the mean Å}
S.E.M. of6 samples.
Fig. 9: Dose-response curves for the antinociceptive effect induced by M-6-G in
sham-operated and sciatic nerve-ligated mice. Groups ofmice were treated s.c.(O.3-30
mglkg, A), i.t.(O.OOI-O.1 nmollmouse, B) or i.c.v.(O.O056-1 nmollmouse, C) with M-6-G 7
days after the nerve ligation. Antinociceptive effects were measured at 45 min, 10 min or 10
min after s.c., i.t. or i.c.v. injection ofM-6-G as the peak time ofM-6-G activity, respectively.
Anti-nociception was expressed as a percentage ofthe maximum possible effect (O/o MPE).
Each value represents the mean Å} S.E.M. of6-11 mice. "pÅqO.05, **pÅqO.Ol, """pÅqO.OOI vs.
sham group.
Fig. 10: Concentration response curve ofM-6-G on the binding of [35S]GTPyS to membranes
of the spinal cord (A), periaqueductal gray matter (B) or thalamus (C) obtained from
sham-operated and sciatic nerve-ligated mice. Membranes were prepared at 7 days after
nerve ligation. Each value represents the mean Å} S.E.M.of 4-6 samples. " "pÅqO.O l vs.
sham group.
Fig. 11: Conditioned place preference produced by s.c. administration ofmorphine (3-1O
mg/kg, A) or oxycodone (O.3-3 mg/kg, B) in sham-operated and sciatic nerve-ligated mice
using the conditioned place preference paradigm. Ordinate: mean difference between time
spent in the post-conditioning test and pre-conditioning test. Immediately after s.c. injection
ofmorphine or oxycodone, mice were placed and conditioned in either comparment for 1 hr.
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Each column represents the mean Å} S.E.M. of7-8 mice. ##pÅqO.Ol, ###pÅqO.OOI vs.
sham-saline group. *pÅqO.05 vs. sham-morphine or sham-oxycodone group. According to
Paxions' atlas (2001), the coronal brain block of the Iower midbrain area (box) was dissected
obtained from 2.5 to 4.5 mm posterior to bregma (C). Effects ofmorphine (D) or oxycodone
(E) on the binding of [35S]GTPyS to membranes of the lower midbrain obtained from
sham-operated and sciatic nerve-ligated mice. Membranes were prepared 7 days after nerve
ligation. Each value represents the mean Å} S.E.M.of4 samples. "pÅqO.05 and ##pÅqO.Ol vs.
sham group.
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Discussion
      The present binding studies clearly suggest that oxycodone possesses high affmity for
MORs in the mouse brain. In contrast, oxycodone showed no affinity for DORs or KORs. In
the [35S]GTPyS binding, the increased level of [35S]GTPyS binding to membranes of the
mouse thalamus induced by oxycodone was abolished by the MOR antagonist P--FNA.
Furthermore, oxycodone failed to affect [35S]GTPyS bindings to membranes of the guinea pig
cerebellum, which is known to be a good source for the possible determination of KOR
agonists. Consistent with these results, s.c. pretreatment with the P-FNA, but not NTI or
nor-BNI, significantly attenuated the oxycodone-induced anti-nociception. Taken together,
these findings suggest that the oxycodone-induced anti-nociception is mainly mediated
through MORs in the CNS, and oxycodone can be classified as the preferential MOR agonist.
However, our notion is inconsistent with the report by Ross and Smith 79). In their report, the
anti-nociception ofoxycodone was antagonized by i.c.v. pretreatment ofnor-BNI with a dose
that failed to affect the antinociceptive effect induced by morphine, suggesting the implication
ofKOR in the oxycodone-induced anti-nociception. Although the specific reason for these
discrepancies between previous studies by Ross and Smith and our studies remains unclear,
one possibility is that the discrepancy may result from different experimental conditions. in
the current study, I have carefu11y confirmed that neither KOR nor DOR agonist-induced
antinociceptive effect is attenuated by pretreatment with P-FNA at the present dose (data not
shown). Additionally, it has been documented that oxycodone acts as the MOR agonist in
mice and binds selectively to the MOR 36). Thus, the present findings further suggest that
MOR, but not KOR, is the primary site for the expression of anti-nociception induced by
oxycodone.
      In the present study,Ialso found that oxycodone showed about 10 times lower ligand
binding affinity than that ofmorphine. On the other hands, morphine and oxycodone were
equipotent antinociceptive agents. It has been recently reported that oxycodone shows lower
efficacy and potency to stimulate [35S]GTPyS binding in the rat spinal cord and PAG than that
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ofmorphine or an oxycodone active metabolite, oxymorphone 36). Although it is difficult to
explain the reason for the lower affinity to the MOR for oxycodone than for morphine, current
evidence demonstrated that oxycodone is actively influxed across the BBB rather than
morphine 6' 92), which could, at least in part, result from this phenomenon.
      In the present study, a neuropathic pain-like state and an inflammatory pain-like state
were suppressed by s.c. treatment with either morphine or oxycodone in a dose-dependent
manner. I proposed that the optimal doses for morphine- or oxycodone-induced
anti-hyperalgesic effect in sciatic nerve-ligated and CFA-treated mice were 5 mglkg or O.5
mgtkg and 3 mgtkg or O.5 mg/kg, respectively. The optimal dose for morphine under a
neuropathic pain-like state showed higher than that under an inflammatory pain-like state.
Unlike morphine, the optimal dose for oxycodone was equipotent between a neuropathic
pain-like state and an infiammatory pain-like state. These results suggest that neuropathic pain
can be relieved by high dose ofmorphine, while the treatment with oxycodone produces a
profound anti-hyperalgesic effect with the same degree under both a neuropathic pain-like
state and an inflammatory pain-like state.
      Using tail-fiick assay, I confirmed that the antinociceptive effect induced by
s.c.-injection of morphine was significantly decreased in sciatic nerve-ligated mice, whereas
sciatic nerve ligation did not alter the effect of oxycodone. However, i.t. and i.c.v.
administration of morphine each produced a significant antinociceptive effect in sciatic
nerve-ligated mice similar to that observed in sham-operated mice. Consistent with these
results, the increase in [35S]GTPyS binding induced by morphine in membrane fractions of the
spinal cord, PAG and thalamus was not altered by sciatic nerve ligation. The present data are
inconsistent with the previous findings that the effect of i.t.-administered morphine was
attenuated under a neuropathic pain-like state in rodents 35' 68' 77' 84). However, recent reports
suggest the data that i.t. treatment with morphine produced greater dose-dependent inhibitions
of neuronal nociception in rodents 20' 88' iOO). Additionally, it has been reported that i.t.
administration with morphine provides analgesia in patients with neuropathic pain syndromes
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3i). Considering these reports, I propose here that the discrepancy and the effectiveness of
morphine may be partly related to the timing ofthe treatment relative to the duration ofthe
neuropathy.
      It is well known that morphine is rapidly converted into two metabolites, M-3-G and
M-6-G Approximately 1O O/o ofmorphine is metabolized to M-6-G and 50 O/o is metabolized
to M-3-G. The fact that M-3-G has very low affmity for MOR and appears to Iack significant
analgesic activity suggests that M-6-G may be the only active metabolite of morphine.
Several studies support the idea that M-6-G directly contributes to the analgesic effects of
morphine 28' 8i' 85). Therefore, I next investigated the antinociceptive effect ofM-6-G in
nerve-ligated mice. S.c., i.t. and i.c.v. administration ofM-6-G each induced a marked
antinociceptive effect in sham-operated mice. Interestingly, M-6-G-induced antinociceptive
effect following each injection was significantly attenuated in nerve-ligated mice compared to
that in sham-operated mice. In addition, the concentration-dependent increases in the binding
of [35S]GTPyS to membranes obtained from the spinal cord and PAq but not thalamus,
stimulated by M-6-G were significantly decreased in nerve-ligated mice compared to those in
sham-operated mice. It is considered that morphine in the brain and spinal cord can not be
converted into M-3-G or M-6-G. These findings suggest that the down-regulation of
M-6-G-sensitive MOR in the spinal cord or PAG area by sciatic nerve injury may result in the
suppression ofthe antinociceptive effect induced by s.c. injection ofmorphine in
nerve-ligated mice.
      It has been reported that s.c.-administered oxycodone is metabolized in the Iiver, and a
large proportion of oxycodone is metabolized to noroxycodone and oxymorphone by way of
N-demethylation and 0-demethylation in the first pass. Current evidence suggests that the
metabolites ofoxycodone including noroxycodone and oxymorphone do not significantly
contribute to its pharmacological effects 22). It has been described that both oxymorphine and
noroxycodone were more potent than oxycodone after intrathecal administration 36). ln the
present study, the increased [35S]GTPyS binding induced by oxycodone in membrane
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fractions of the spinal cord, PAG and thalamus and the anti-nociception induced by s.c., i.c.v.
and i.t. administration of oxycodone were not changed by sciatic nerve ligation compared to
those in sham-operated mice. Although it remains to be seen the discrepancy of the report
regarding the anti-nociception ofmetabolites ofoxycodone, the present data provide evidence
that oxycodone may be a usefu1 alternative to morphine in the treatment ofneuropathic pain.
      Another key finding in the present study is that the rewarding effects of
s.c.-administered morphine or oxycodone under a neuropathic pain-like state were suppressed
following sciatic nerve ligation. The mesolimbic dopaminergic system, which projects from
the VTA ofthe midbrain to the nucleus accumbens (N.Acc.), has been identified as the critical
substrate of the reinforcing effects of opioids i4' i6' 54). considering these findings, I next
assessed changes in the ability ofmorphine or oxycodone to activate G-proteins in the lower
midbrain area including the VTA of sham-operated and sciatic nerve-ligated mice by
monitoring the binding of [35S]GTPyS to membranes. The increase in the binding of
[35S]GTPyS to lower midbrain membranes in nerve-ligated mice stimulated by morphine or
oxycodone was significantly lower than that observed in sham-operated mice. It has been
reported that intra-VTA administration ofDAMGO caused a dose-dependent preference for
drug-associated place 54), and also demonstrated that the enhancement of DA release in the
N.Acc. stimulated by morphine was significantly suppressed by sciatic nerve ligation 69).
Furthermore, it was reported that sciatic nerve ligation caused a dramatic reduction in the
activities ofextracellular signal-regulated kinase (ERK) in the tyrosine hydroxylase-positive
dopaminergic neuron ofthe VTA 70). These findings suggest that the reduction in
MOR-mediated G-protein activation in the lower midbrain area caused by sciatic nerve
ligation may be responsible for inhibiting the rewarding effects induced by both morphine and
oxycodone under a neuropathic pain-like state.
      In conclusion, these findings provide further evidence that treatment with oxycodone
produces a profound antinociceptive effect under a neuropathic pain-like state, with a less or
less ofa rewarding effect. Furthermore, the reduction in G-protein activation induced by
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M-6-G in the spinal cord and PAG may, at least in part, contribute to the suppression of the
antinociceptive effect produced by morphine under a neuropathic pain-like state.
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                            Chapter 3
Differential activation of the p-opioid receptor by oxycodone and morphine in
      pain-related brain regions in a bone cancer pain model
83
                                Introduction
      Cancer pain is treated using various therapeutic modalities, including non-steroidal
anti-inflammatory drugs, opioids, radiation, and surgical intervention 38). For advanced cancer
pain, opioids are often the mainstay of analgesic therapy iO' 30' 78); however, opioids are often
insufficient in treating bone cancer pain 49' 78). Recent studies have shown that morphine has
different effects on bone cancer pain and inflammatory pain in animal models 40' 98), and that
higher doses ofmorphine are required to obtain significant analgesic effects in a bone cancer
pain model than in an inflammatory pain model. In the clinical setting, oxycodone effectively
relieves bone cancer pain 3' 4' i7' 22' 27' 86' 96' 97). previously, it has been reported that oxycodone
inhibited different pain-related behaviours in femur bone cancer (FBC) and nociceptive pain
models over a similar dose range, whereas morphine was less effective in the FBC models 5i).
These results suggested that oxycodone had a unique, distinct analgesic profile in bone cancer
pain.
      This study investigated the mechanism underlying the unique analgesic profile of
oxycodone by comparing it with morphine in a bone cancer pain model. One potential
mechanism -differential activation of the MOR by oxycodone and morphine under the bone
cancer pain-was observed in this model.
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                            Materials and Methods
Animals
      C3H!HeN mice (body weight 18-23 g) (CLEA Japan, Tokyo, Japan) were used in this
study. The animals were housed in a room maintained at 23Å}1OC under a 12-hr lightl12-hr
dark cycle and allowed access to water and food ad libitum. All procedures for the animal
experiments were approved by the Animal Care and Use Committee of Shionogi Research
Laboratories, Osaka, Japan in agreement with the internal guidelines for animal experiments
and in adherence to the ethics policy of Shionogi & Co.
Drugs
      Oxycodone (oxycodone hydrochloride) and morphine (morphine hydrochloride) were
from Shionogi & Co. (Osaka, Japan). P-Funaltrexamine hydrochloride (P-FNA), [D-Ala2,
N-Me-Phe4, Gly5-ol] enkephalin (DAMGO), and nor-binaltorphimine dihydrochloride
(nor-BNI) were purchased from Tocris Bioscience (Bristol, UK). All drugs were dissolved in
O.90/o physiological saline (Otsuka Pharmaceutical, Tokyo, Japan) for in vivo experiments and
dissolved in the appropriate assay buffer for in vitro experiments.
The FBC model
      The NCTC2472 tumor cells (American Type Culture Collection, Manassas, VA,
USA) were maintained in Dulbecco's modified Eagle's medium (DMEM; Invitrogen,
Carlsbad, CA, USA), supplemented with 1OO/o foetal bovine serum (FBS; Invitrogen), 100
unitslml penicillin, and 100 pglml streptomycin (Invitrogen) and cultured at 37 Å} O.20C in a
humidified atmosphere of50/o C02. To prepare the FBC model, the NCTC2472 tumor cells
were injected following a previously described protocol 24' 5i). ln brief, C3HIHeN mice were
anesthetized with 30/o isoflurane, and a left knee arthrotomy was performed. Tumor cells (1 Å~
105 cells in 5 pl ofHank's balanced salt solution [Invitrogen]) were injected directly into the
medullary cavity ofthe distal femur, and the drill hole in the bone was closed with resin
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cement (ADFA; Shofu, Kyoto, Japan). In the sham group, 5 pl ofHank's balanced salt
solution were injected instead ofthe tumor cells in the same manner. Fourteen days after
tumor implantation, pain-related behavior(s) was evaluated to confirm the phenotypic
behaviour of the FBC model using previously described protocols 5i). Mice showing guarding
times that changed from O-2 sec (before tumor implantation) to 8-16 sec were used for the in
vitro experiments, and mice showing the above change in the guarding times and limb-use
abnormality score that produced more than 3 on the ipsilateral side (14 days after tumor
implantation) were used for the in vivo experiment.
Measuments of B... and Kd for MOR using the
(tyIosil-3,5-(3)H(N)]-ID-Ala(2),N-Me-Phe(4),Gly-ol(5))enkephalin ({3H]DAMGO)
      Tissue samples were prepared from sham operated mice and from FBC model mice
showing guarding behavior for 8-16 sec 14 days after the surgery. The PAG, region ventral to
the PAG including red nucleous (vPAG; which does not contain the PAG.), mediodorsal
thalamus (mTH), ventral thalamus (vTH), and ipsilateral spinal cord were removed quickly
after decapitation. Briefly, refening to the mouse brain atlas 73), a coronal block of the PAG
and vPAG was obtained from 2.7 to 3.7 mm posterior to the bregma, and a coronal block of
the mTH and vTH was obtained from 1.0 to 2.0 mm posterior to the bregma. The collected
tissues were then transferred to a tube fi11ed with ice-cold sucrose (320 mM). The tissues were
homogenated by the high velocity revolution homogenizer. The homogenate was centrifuged
at 40C for 20 min at 2,OOOg, and the supernatant was centrifuged at 40C for 20 min at 48,OOOg.
The pellet was resuspended in ice-cold assay buffer containing 50 mM Tris-HCI (pH 7.4), 5
mM MgC12, and 1 mM EDTA as the membrane fraction. The membrane proteins were
quantified using a bicinchoninic acid (BCA) compatible protein assay kit (Pierce) with bovine
serum albumin (BSA) as the standard. The amount ofprotein used in each assay was adjusted
to within the range 1OO-150 pg depending on the region.
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      A saturation binding experiment was performed in duplicate with increasing
concentrations of [3H]DAMGO (O.5-16 nM; specific activity, 59.0 Cilmmol; PerkinElmer
Life Science, Arlington Heights, IL) in a final volume ofO.5 ml. The binding assay
preparation was incubated in the assay buffer (50 mM Tris-HCI (pH 7.4), 5 mM MgC12, and 1
mM EDTA) for 1 hr at 250C, and non-specific binding was determined in the presence of 1O
pM DAMGO. The binding was terminated by rapid filtration through Whatman GFIC glass
filters (Brandel, Gaithersburg, MD, USA). The filters were then washed three times with 50
mM Tris-HCI, pH 7.4 and transferred to scintillation vials. Next, 5 ml ofClear-sol 2 (Nacalai
Tesque, Kyoto, Japan) were added to the vials. Radioactivity in the samples was determined
using a liquid scintillation analyser.
Guanosine-5'-o-(3-thio) triphosphate ((35S]GTPyS) binding assay
      Tissue samples were prepared from sham operated mice and from FBC model mice
showing guarding behavior of 8-16 sec 14 days after the operation. The PAG, vPAG, mTH,
vTH, and ipsilateral spinal cord were removed quickly after decapitation, as described above.
The collected tissues were then transferred to tubes fi11ed with ice-cold 50 mh Tris-HCI
buffer, pH 7.4, 5 mM MgC12 and 1 mM EDTA. The membrane homogenate (5-10 pglassay)
was prepared as described previously 59) and incubated at 250C for 2 hr in O.5 ml ofassay
buffer (50 mM Tris-HCI, pH7.4, 5 mM MgC12, 1 mM EDTA and 100 mM NaCl) with various
concentrations ofthe opioid agonist, 30 pM guanosine-5'-diphosphate (GDP) and 50 pM
[35S]GTPyS (specific activity, 1OOO Cilmmol; PerkinElmer Life Science, Arlington Heights,
IL). Agonist (oxycodone or morphine) and antagonist (6-FNA or nor-BNI) were applied
simultaneously and co-incubated (Fig. 2E, 2F, 3E, 3F, and 4C). It has been reported that the
GTP activity ofmorphine is not inhibited by a DOR antagonist or a KOR antagonist but is
completely antagonized by P-FNA, a MOR antagonist under the similar co-incubation method
(Nakamura et al., in preparation), suggesting that the P-FNA treatment in the present study
selectively antagonized the MOR activity. The reaction was terminated by filtration using
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Whatman GFIC glass filters (Brandel, Gaithersburg, MD, USA) that had been presoaked in 50
mM Tris-HCI, pH 7.4, and 12.5 mM MgC12 at 40C for 2 hr. The filters were washed three
times with 5 ml of ice-cold 50 mM Tris-HCI buffer, pH 7.4, and then transferred to
scintillation-counting vials. Then, 5 ml ofClear-sol 2 (Nacalai Tesque, Kyoto, Japan) were
added to the vials. Radioactivity in the samples was determined using a liquid scintillation
analyser. Nonspecific binding was measured in the presence of 1O pM unlabelled GTPyS.
G-protein activation by each agonist was expressed as the percent stimulation, which was
calculated as (Ti - To)1(T2 - To) Å~ 1OO, where To is the nonspecific activity, Ti is the
[35S]GTPyS activity in the presence ofvarious concentrations ofoxycodone or morphine, and
T2 is the [35S]GTPyS activity in the absence of the agonist. The inhibition ratio ofG-protein
activation between samples from the tumor-implanted and sham-operated mice was reported
as the percent inhibition in each opioid, which was calculated as 1OO - (T31T4) Å~ 1OO, where
T3 is the percent stimulation value ofthe tumor-implanted mice samples treated with either
1Ofi5 M oxycodone or morphine and T4 is the percent stimulation value of the sham-operated
mice samples treated with 1OL5 M ofthe respective opioid.
Measument of MOR binding affinities of oxycodone and morphine using [3HIDAMGO
      The MOR binding affinities were measured by displacement of [3H]DAMGO. Sample
preparation, the amount ofmembrane proteins, composition ofassay buffer, incubation time
and filtration method were the same as the method described above (Measuments ofBmax and
Kd for MOR using the [3H]DAMGO). The MOR binding of each agonist was measured by
displacement of [3H]DAMGO (2 nM) binding by different concentrations of oxycodone
(1O-iO-lo'6 M) or morphine (1O-iO-1O-6 M), and was expressed as O/o of [3H]DAMGO binding,
in which the [3H]DAMGO binding in the absence ofoxycodone or morphine was defined as
IOOO/o. The value of each sample was calculated as: (Ti - To) 1 (T2 - To) Å~1OO, where To is the
nonspecific binding, Ti is the [3H]DAMGO binding in the presence ofvarious concentration
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of oxycodone or morphine, and T2 is the [3H]DAMGO binding in the absence of respective
agonlst.
Measuring pain-related behavior in the FBC model
      Before evaluation, the mouse was placed in a clear plastic observation box and
allowed to habituate for 15 min. Spontaneous guarding behavior, i.e., the amount oftime the
hind paw on the ipsilateral side was lifted during ambulation, was assessed for a 2-min
observation period. Limb-use abnormality on the ipsilateral side during spontaneous
ambulation was scored on a scale ofO to 4: O, normal limb use; 1, slight limp; 2, obvious
limp; 3, partial non-use ofthe limb; and 4, complete non-use ofthe limb.
      Allodynia-like behavior was recognized as paw withdrawal in response to tactile
stimuli using a series ofvon-Frey monofilaments (pressure: O.O08, O.02, O.04, O.07, O.16, O.4,
O.6, and 1 g). The up-down method of the von Frey monofilament test iOO) was used, as
described previously 5i).
      The effects on guarding time and limb-use abnormality were expressed as the
percentage maximum possible effect (MPE), which was calculated as ([To - Ti] Å~ 1OOITo),
where To and Ti are the values (time or score) before and after admjnistering the agonist in
each animal, respectively. The inhibition of allodynia-like behavior was expressed as the
percentage MPE, which was calculated as ([T2 - Ti] Å~ 1OOI[To - Ti]), where To is the
threshold stimulation (g) before tumor implantation, and Ti and T2 are the respective
threshold stimulations (g) before and after administering the agonist in each animal.
Tail-fiick test
      The anti-nociceptive effects of oxycodone and morphine were determined by the
tail-flick test (UGO-BASILE, Comerio, VA, Italy). The intensity ofthe heat stimulus was
adjusted so that the animal flicked its tail within 2-4 s after the application ofthe stimulus,
Anti-nociceptive effect was expressed as a percentage ofthe MPE and was calculated by (Ti -
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To) Å~ 100 1 (T2 - To), where To and Ti are the tail-flick latencies before and after the
administration of opioid agonist, respectively, and T2 is the cut-off time (set at 10 s) in the
tests to avoid damage to the tail.
Intracerebroventricular Administration
      Intracerebroventricular (i.c.v.) drug administration was performed as described
previously, with some modifications 56). The day before i.c.v. administration, the mice were
anesthetized briefiy with 30/o isoflurane, and a 2-mm double-needle (tip: 27G, 2 mm; base:
22G, 10 mm, Natsume Seisakusyo, Tokyo, Japan) attached to a 25-pl Hamilton microsyringe
was inserted into a unilateral injection site in order to make a hole in the skull for injection.
The unilateral injection site was approximately 2 mm caudal and 2 mm lateral-from the
bregma, and the needle was inserted perpendicular to the sku11. When drugs were
administered, the injection volume was 2 pl for each mouse. Each solution was injected
without injection cannulae.
Statistical analysis
      The data are expressed as mean Å} standard error ofmean (S.E.M.). SAS (ver. 8) and
GraphPad Prism 4.0 were used for the statistical analysis. The Kd and B.a. of saturation
binding and the concentration of 500/o inhibition (ICso) of displacement binding were
calculated using GraphPad Prism 4.0. The dose producing 500/o ofthe effect (EDso) and ICso
were determined from the regression analysis. The dose-dependent analgesic response,
G-protein activation, and receptor binding curves were fitted using GraphPad Prism 4.0. The
statistical significance of differences among groups was assessed using two-way analysis of
variance (ANOVA) followed by Dunnett's or Bonferroni multiple comparison tests. A
probability value (P) ofÅq O.05 was considered to be statistically significant.
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                                   Results
Reduction in MORs on cell membranes in supraspinal sites and the spinal cord in the
FBC model
      One of the possible mechanisms by which opioid potency in bone cancer pain is
reduced is via a reduction in MORs. Therefore, I examined whether the total number of
MORs was affected in chronic bone cancer pain in the FBC model by measuring the B.,. and
Kd of the MOR (Fig. 1).
      I evaluated [3H]DAMGO saturation binding to cell membranes prepared from
pain-related regions, including the PAG (Fig. IA), vPAG (Fig. IB), thalamus (mTH or vTH;
Fig. IC, D), and spinal cord (Fig. IE) in sham-operated and tumor-implanted mice. High
specific binding of [3H]DAMGO was observed in membrane samples prepared from the
mouse brain regions and spinal cord, and specific binding increased linearly with protein
concentration up to 400 pg (data not shown). Figure 1 shows the saturation curves of
[3H]DAMGO (O.5-16 nM) binding to membrane samples from the PAG , vPAG, mTH, vTH,
and spinal cord in sham-operated and tumor-implanted mice. The values'ofBm,. and Kd
calculated using Scatchard plot analysis showed that the B.,. of [3H]DAMGO decreased
significantly by 15Zl50/o in all regions in tumor-implanted mice as compared with
sham-operated mice, while the Kd of [3H]DAMGO binding did not differ significantly
between sham-operated and tumor-implanted mice (Fig. IF). This showed that the total
amount ofMORs on tissue membranes was reduced in the brain regions and spinal cord in the
FBC model mice.
Different activation of GTPyS binding by oxycodone and morphine in the supraspinal
sites and spinal cord in the FBC model
      In order to examine the mechanism underlying the distinct analgesic profiles of
opioids, I investigated the MOR agonist activities of oxycodone and morphine in several
pain-related regions in the FBC model (Fig. 2-5).
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      In the PAG, oxycodone (10-8-10-5 M) increased [35S]GTPyS binding in a
concentration-dependent manner, but the maximum activation (E.,.) of [35S]GTPyS binding
was reduced in tumor-implanted mice (E... = 38.60/o) as compared with control mice (Emax ==
51.60/o) (Fig. 2A). Morphine (1O-8-1O-5 M)-induced G-protein activation was also attenuated
in tumor-implanted mice (E.a.: tumor-implanted mice = 25.20/o, sham control mice = 72.60/o)
in the PAG (Fig. 2C). In the vPAG, the difference between the two opioids was more
apparent. Similarly, oxycodone (10N8-1O-5 M) induced G-protein activation in both
tumor-implanted (E.,.=38.80/o) and sham-operated (E...=42.90/o) mice (Fig. 2B), while MOR
activation by morphine (1OT8-1O-5 M) was significantly attenuated in the tumor-implanted
mice (Emax = 27.30/o) as compared with sham control mice (E.,. = 64.50/o) (Fig. 2D).
      A similar result was observed for the mTH; oxycodone (1O'8-1O-5 M)-induced
G-protein activation was reduced in tumor-implanted mice (E.a.: sham-operated mice =
57.00/o, tumor-implanted mice = 41.30/o), and the morphine effect was significantly and more
severely attenuated in tumor-implanted mice (E.,.: sham-operated mice = 81.50/o,
tumor-implanted mice = 44.60/o) (Fig. 3A, C). By contrast, the effects ofoxycodone and
morphine on G-protein activation in the vTH (E.,. in sham-operated mice: oxycodone =
39.90/o, morphine = 102.70/o) were not altered in tumor-implanted mice (Emax in
tumor-implanted mice: oxycodone = 34.1O/o, morphine == 106.20/o) (Fig. 3B, D). In the
ipsilateral spinal cord of sham control mice, both oxycodone and morphine produced
concentration-dependent G-protein activation (E...: oxycodone==46.60/o, morphine=85.1O/o)
and Emax was attenuated in the tumor-implanted mice (E.,.: oxycodone = 32.20/o, morphine =
38.90/o) (Fig. 4).
      GTP binding induced by oxycodone and morphine in the brain regions and spinal cord
was inhibited completely by P-FNA (10'6 M), a MOR-selective antagonist, but not affected
by nor-BNI (10r6 M), a KOR-selective antagonist. These results confirm that the observed
GTP binding was predominantly due to MOR activation (Figs. 2E, F, 3E, F, and 4C).
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      The ratio ofthe inhibition ofMOR activation in the tumor-implanted group to that in
the sham-operation group was compared between the two opioids at the maximum
concentration (10'5 M) (Fig. 5). In the PAG, vPAG, and mTH, the activation of MOR was
reduced more severely (i.e., the percent inhibition was increased significantly) in the
morphine-treated group (PAG == 65.30/o, vPAG =: 57.50/o, and mTH = 46.00/o) as compared
with the oxycodone-treated group (PAG = 18.90/o, vPAG = 1 1.50/o, and mTH = 26.80/o). By
contrast, the effects ofthe two opioids were reduced similarly in the spinal cord (oxycodone
43.20/o, morphine 54.50/o). Thus, the functional activation by oxycodone and morphine was
attenuated in several regions related to pain signalling with tumor implantation; interestingly,
the activation by morphine was attenuated more severely than that by oxycodone in the mTH,
PAG, and vPAG.
No change in binding affinity of oxycodone or morphine to MOR in the supraspinal sites
and spinal cord in the FBC model
      I next investigated whether the MOR binding affmity was reduced depending on the
agonists under the bone cancer pain condition. I performed competitive displacement-binding
assay of [3H]DAMGO with different concentrations (1O-iO-1O-6 M) ofunlabeled opioid
agonist using membrane samples from sham-operated and tumor-implanted mice (Fig. 6). The
[3H]DAMGO binding was displaced by oxycodone or morphine in a concentration-dependent
manner in the membrane samples from all regions (Fig. 6A-E). wnen the levels of
[3H]DAMGO displacement were compared between the sham-treated group and the
tumor-implanted group in the respective opioids, displacement curves were similar between
two groups, suggesting that affinities ofthese two opioids to MOR were not altered in the
FBC model (Fig. 6A-E). The ICso value ofeither oxycodone or morphine did not differ
significantly between sham-operated and tumor-implanted mice (Fig. 6F). These results
suggest that the change in the MOR binding affinity is not a likely mechanism for the
agonist-dependent attenuation ofthe MOR activation under the bone cancer pain condition.
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Analgesic effects induced by the intracerebroventricular administration of oxycodone
and morphine in the FBC model
      Since the proportionate reduction of GTPyS stimulation was distinct for morphine
compared to oxycodone in the pain-related supraspinal sites, I next examined whether the
analgesic effects ofsupraspinal oxycodone and morphine were affected in the FBC model
(Fig. 7).
      The i.c.v. administration ofoxycodone (O.02-1.0 pglmouse) reduced the guarding
time and limb-use abnormality score and reversed the lowered paw withdrawal threshold in
the FBC model (Fig. 7), indicating that oxycodone dose-dependently ameliorated all
pain-related responses. The highest dose (1.0 pglmouse) had a 91O/o MPE for guarding
behavior, 760/o MPE for limb-use abnormality, and 960/o MPE for allodynia-like behavior. The
i.c.v. morphine produced dose-dependent analgesic effects on guarding (O.05-2.0 pgtmouse)
(Fig. 7A) and allodynia-like (O.05-O.5 pg!mouse) behaviors (Fig. 7C), but did not improve
limb-use abnormalities in the dose range used (O.05-2.0 pglmouse) (Fig. 7B). The highest
dose of morphine exhibited 650/o MPE for guarding behavior and 500/o MPE for allodynia-like
behavior.
      Table 1 shows the EDso values of the analgesic effects ofi.c.v. oxycodone and
morphine on the pain-related behavious calculated using regression equations. The EDso of
i.c.v. oxycodone for guarding, limb-use, and allodynia-like behaviors was O.096, O.28, and
O.097 pglmouse, respectively. The EDso ofmorphine for guarding and allodynia-like
behaviors was O.69 and O.50 pglmouse, respectively, while the EDso for the limb-use
abnormality could not be calculated because morphine did not improve limb-use
abnormalities in the dose range (O.05-2.0 pg!mouse). This shows that oxycodone had
approximately 5-7 times greater potency for the inhibition of guarding and allodynia-like
behaviors than morphine, and that overall analgesic potency is greater than morphine with
i.c.v. administration in the FBC model.
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      In order to compare the analgesic potency of oxycodone and morphine under the
sham-operated condition, I compared anti-nociceptive potency of i.c.v. administered
oxycodone and morphine in sham-operated mice using tail-flick test. The i.c.v.
administration ofboth oxycodone (O.3-10 pglmouse) and morphine (O.3-10 pglmouse)
dose-dependently increased the tail-fiick latency in sham-operated mice with 1OO O/o MPE at
the highest dose (10 pglmouse) (data not shown). The EDso values were O.28pg!mouse in
oxycodone treated groups and O.23pglmouse in morphine treated groups (Table 1), showing
that both oxycodone and morphine possess the similar anti-nociceptive potency in the
sham-operated mice.
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                                Figure legends
Fig. 1: Saturation curves for the specific binding of[3H]DAMGO on cell membranes ofPAG,
vPAG, mTH, vTH, and spinal cord prepared from sham-operated and FBC model mice. Tissue
samples were collected 14 days after the sham operation (Sham) or tumor implantation
(tumor-implanted), and membranes prepared from the PAG (A), vPAG (B), mTH (C), vTH
(D), and spinal cord (E) were used for the binding assay. [3H]DAMGO binding was examined
using concentrations from O.5-16 nM. Specific binding was defined as the difference in
binding observed in the absence and presence of 1 O pM unlabelled DAMGO. Each value
represents the mean Å} S.D. oftwo independent experiment (8 mice/sample in each
experiment). A similar result was observed in a separate experiment. The Kd and Bmax of
[3H]DAMGO in those regions are shown in (F). The values were determined from the
saturation curves and Scatchard plots analysis, and at least six concentrations were used for
each analysis. ""*p Åq O.OOI vs. sham group (two-way ANOVA, Dunnett's multiple
comparison test).
Fig. 2: Concentration-response curves of oxycodone and morphine for [35S]GTPyS binding to
cell membranes ofPAG and vPAG. The cell membranes ofPAG (A, C) and vPAG (B, D) were
prepared 14 days after the sham operation (Sham) or tumor implantation (tumor-implanted)
and incubated in the presence ofdifferent concentrations ofoxycodone (1O-8-1O-5 M) (A, B)
or morphine (1Or8-1Or5 M) (C, D). The membrane-bound [35S]GTPyS was measured and
expressed as the percent stimulation relative to the basal level. Each symbol represents the
mean Å} S.E.M. ofthree independent samples (four mice/sample). The effects ofthe p-opioid
receptor antagonist 6-FNA (1O-6 M) and K-opioid receptor antagonist nor-BNI (1Or6 M) on
oxycodone- (1Or5 M) or morphine- (1O"5 M) induced [35S]GTPyS binding in the PAG (E) and
vPAG (F) oftumor-implanted mice are also shown. Each column represents the mean Å}
S.E.M. ofthree independent samples (four mice/sample). In each graph, the y-axis indicates
the percentage ofG-protein activation by each agonist. F(i,2s)= 4.822; "p Åq O.05 vs. sham
oxycodone group, Fa2s)= 9.203; ##p Åq O.Ol or F(i,2s)=: 18.94; ###p Åq O.OOI vs. sham morphine
103
group (two-way ANOVA; A, C, or D). 'p Åq O.05 or "p Åq O.O1 vs. sham morphine group
(Bonferroni multiple comparison post test; C). *"*p Åq O.OO1 vs. oxycodone alone group,
#uapÅqO.OOI vs. morphine alone group (two--way ANOVA, Dunnett's multiple comparison test;
E or F).
Fig. 3: Concentration-response curves ofoxycodone and morphine for [35S]GTPyS binding to
cell membranes from the mTH (A, C) and vTH (B, D). The membranes were prepared 14
days after the sham operation (Sham) or tumor implantation (tumor-implanted) and incubated
in the presence ofdifferent concentrations ofoxycodone (1O-8-1O-5 M) (A, B) or morphine
(10-8-1O-5 M) (C, D). The membrane-bound [35S]GTPyS was measured and expressed as the
percent stimulation relative to the basal level. Each symbol represents the mean Å} S.E.M. of
three independent samples (four mice/sample). The effects of B-FNA (1O'6 M) and nor-BNI
(1O-6 M) on oxycodone- (1O'5 M) or morphine- (10-5 M) induced [35S]GTPyS binding in the
mTH (E) and vTH (F) of tumor-implanted mice are also shown. Each column represents the
mean Å} S.E.M. ofthree independent samples (four micelsample). In each graph, they-axis
indicates the percent of G-protein activation by each agonist. Fa2s) =: 1O.71; ##p Åq O.O1 vs.
sham morphine group (two-way ANOVA; C). *p Åq O.05 or ""p Åq O.O1 vs. oxycodone alone
group, ###p Åq O.OO1 vs. morphine alone group (two-way ANOVA, Dunnett's multiple
comparison test; E or F).
Fig. 4: Concentration-response curves ofoxycodone and morphine on [35S]GTPyS binding to
cell membranes ofthe ipsilateral spinal cord. Spinal cord cell membranes (A, B) were
prepared 14 days after the sham operation (Sham) or tumor implantation (tumor-implanted)
and incubated in the presence of different concentrations ofoxycodone (1O-8-10-5 M) (A) or
morphine (10-8-10'5 M) (B). The membrane-bound [35S]GTPyS was measured and expressed
as the percent stimulation from the basal level. Each symbol represents the mean Å} S.E.M. of
three independent samples (four mice/sample). The effects ofP-FNA (1Orm6 M) and nor-BNI
(1O-6 M) on oxycodone- (1O-5 M) or morphine- (1075 M) induced [35S]GTPyS binding in the
spinal cord (C) of tumor-implanted mice are also shown. Each column represents the mean Å}
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S.E.M. of three independent samples (four mice/sample). In each graph, the y-axis indicates
the percent ofG-protein activation by each agonist. F(i,2s)= 34.41; **"p Åq O.OO1 vs. sham
oxycodone group, Fa2s) = 8.252; #p Åq O.05 vs. sham morphine group (two-way ANOVA; A or
B). "'p Åq O.OOI vs. sham oxycodone group or "p Åq O.O1 vs. sham morphine group
(Bonferroni multiple comparison post test; A or B). ""p Åq O.Ol vs. oxycodone alone group,
ma#p Åq O.OO1 vs. morphine alone group (two-way ANOVA, Dunnett's multiple comparison test;
C).
Fig. 5: Change in the maximum activation ofMOR by oxycodone and morphine in the FBC
model. The activation ofMOR was determined by the [35S]GTPyS assay, and the levels
stimulated by oxycodone (10-5 M) or morphine (10-5 M) were compared between the sham
and tumor-implanted groups. The y-axis represents the inhibition ratio ofG-protein activation
in the samples from the tumor-implanted mice as compared with those from the
sham-operated mice. Each column represents the mean Å} S.E.M. ofthree independent
experiments. The inhibition ratio ofG-protein activation between samples from the
tumor-implanted and sham-operated mice was caluclated as the percent inhibition in each
opioid as described in the text. The variability ofthe inhibition ratio was determined by the
variability of the ratio of the GTP activation between the tumor-implanted and sham-operated
group among the three experiments, and therefore the S.E.M. values in this figure is different
from those in figure 2-4. "p Åq O.05, ""p Åq O.O1 vs. oxycodone group (two-way ANOVA,
Dunnett's multiple comparison test).
Fig. 6: Displacement ofthe [3H]DAMGO binding on membranes of PAq vPAq mTH, vTH
and spinal cord by oxycodone or morphine. Tissue samples were collected on 14 days after
sham-operation (sham) or tumor-implantation (tumor-implanted), and membrane prepared
from PAG (A), vPAG (B), mTH (C), vTH (D) and spinal cord (E) were used for the
displacement assay. Experiments were performed in the presence of [3H]DAMGO (2 nM) and
increasing concentrations ofoxycodone (1O-iO-1O-6 M) or morphine (1O-!O-1o-6 M). The
specific binding was defined as the difference in bindings observed in the absence and
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presence of 10 pM unlabeled DAMGO. Each column represents the mean Å} S.E.M. of three
independent samples (8 mice/sample). The ICso values ofoxycodone and morphine were
shown in (F). The ICso values were determined by analysis ofvariance and linear regression
techniques, and at least nine concentrations were used for each analysis. Values in parentheses
indicate the 950/o confidence range.
Fig. 7: Dose-response curves for the analgesic effects induced by i.c.v. oxycodone and
morphine in the FBC model. The analgesic effects of oxycodone (O.02-1 pglmouse, i.c.v.)
and morphine (O.05-2 pglmouse, i.c.v.) on on-going pain, ambulatory pain, and the
allodynia-like response were evaluated based on guarding behaviour (A), limb-use
abnormalities (B), and the von-Frey test (C). FBC model mice were used 14 days after tumor
implantation, and the analgesic effects were determined 10 min after opioid administration.
The y-axes represent the percent MPE of the analgesic effect. Data plotted are the mean Å}
S.EM of 6-8 mice.
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Discussion
      In this study, I found that MOR activation by oxycodone and morphine was attenuated
in the PAG, vPAG, mTH, and spinal cord in the FBC model. In addition, the attenuation of
MOR activation by oxycodone was less than that ofmorphine in supraspinal regions, such as
the PAG, vPAG, and mTH. Therefore, in bone cancer pain, MOR activation in the brain
regions related to pain signalling was modified in an agonist-dependent manner. Consistent
with this, when the analgesic effects of intracerebroventricular oxycodone and morphine were
examined using three different pain-related behaviours in the FBC model, the overall
analgesic potency ofoxycodone was greater than that ofmorphine.
      Bone cancer pain is often insufficiently controlled by opioids 49' 78). The FBC model is
a good animal model for investigating the mechanisms ofbone cancer pain 24' 5i), because this
model mimics some clinical features of human bone cancer pain 29' 72). For example,
pathological changes, such as bone destruction and nerve compression, appear within a few
weeks after the implantation of tumor cells 40' 5i). Since It has been reported that oxycodone
has a unique analgesic profile as compared with other opioids in this model 5i), the
mechanism underlying the distinct analgesic effects of oxycodone in bone cancer pain can be
investigated.
      In the receptor binding assay, FBC mice exhibited a marked decrease in the Bmax of
[3H]DAMGO binding without affecting the Kd in pain-related regions, indicating that the
number of MORs on cell membranes was reduced in bone cancer pain. Yamamoto et al. 98)
reported that MOR levels were reduced in the spinal cord and dorsal root ganglion in bone
cancer pain model mice. In this study, I also found a reduction in MORs, not only in the
spinal site, but also in the supraspinal region. The reduction in MORs may result from the
phosphorylation andlor internalization of MORs with the continuous release of endogenous
opioids. It has been reported that pain and electrical stimulation induces the release of
endogenous opioids in the brain 99' iOi), and the endogenous opioids rectify pain by stimulating
the MOR as an internal compensation system. Although I did not measure endogenous opioid
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release in this model, perhaps such a change in the endogenous opioid level plays a role in the
reduction in MORs on cell membranes in pain-related regions.
      These results showed that reduction in the MOR levels depended on the brain regions.
When I analyzed the relationship between changes in the MOR levels and changes in the GTP
activities by oxycodone and morphine, consistent correlation was not observed. For example,
while both reduction in the number of MOR and that in the opioid-activated GTP level were
relatively small at the vTH compared with other regions, the reduction in the MOR level was
only 250/o in PAG, although the morphine-activated GTP level was more severely decreased
(as about 600/o reduction) at the PAG. These results showed that the magnitude ofthe change
in the MOR level does not simply reflect the magnitude ofthe change in the agonist activity
level.
      One ofmy main findings was the limited attenuation ofMOR activation (measured by
GTPyS binding activity) induced by oxycodone as compared with morphine in the
pain-related regions in bone cancer pain. There are at least three possibilies for the
mechanisms those may explain the agonist-dependent attenuation ofthe MOR activation; 1) a
change in the number of MOR, 2) a change in the MOR binding affinity, and 3) a change in
regulatory mechanismofG-protein activation, It has been reported that agonist activity ofa
partial agonist tends to be more affected by the change in the number ofreceptors than that of
a fu11 agonist i2' 45). Since my data and the previous studies by others 36) showed that
oxycodone is a more nearly partial agonist than morphine, a reduction of the MOR level in
FBC model mouse would be expected to affect MOR agonist activity of oxycodone more than
that ofmorphine, However, this result was contrary to this prediction, and therefore this
possibility is unlikely. The second possibility is that the MOR binding affinity was reduced
depending on the agonists under the bone cancer pain condition. However, when I examined
whether the MOR binding affinities ofoxycodone and morphine were affected in the FBC
model, no significant change was observed in the displacement levels of [3H]DAMGO
binding by either oxycodone or morphine between the tumor-implanted mice and
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sham-operated mice. This suggests that the change in the MOR binding affmity is not a likely
mechanism for the attenuation of the MOR activation. The third possibility is that a regulatory
mechanism of GDP-GTP exchange is responsible for the underlying mechanism of the
agonist-dependent modulation in the FBC model. Since I used a non-hydrolysable analogue
ofGTP ([35S]GTPyS) in this study, the processes involved in GTP hydrolyzation can not
account for the differences in GTP stimulation, and the distinct MOR activation caused by
oxycodone and morphine are likely due to the cellular processes following ligand binding to
the receptors, before Gct-GDP is exchanged for Gor-GTP. Thus, the differentially activated
MOR by oxycodone and morphine might be due to the mechanism that regulates the binding
ofGTP to G-proteins in the FBC model. My hypothesis might be supported by previous
report that GDP-GTP exchange factor modulated the agonist-induced pharmacological effect
5). However, little is known about importance ofthe GDP-GTP exchange mechanism in the
regulation ofGTP activation by opioid agonist. Further study is required to identify the
underlying mechanism of the observed agonist-dependent effect.
      Since oxycodone and morphine activate MOR differently in pain-related brain regions,
the supraspinal administration ofoxycodone and morphine leads to distinct analgesic effects
in the FBC model. While the i.c.v. oxycodone and morphine had equipotent anti-nociceptive
effects in the sham operated mouse ofFBC (C3HIHeN mouse; Tablel), the i.c.v. oxycodone
had 5-7 times greater analgesic potency than morphine in the evaluation of guarding and
allodynia-like behaviours in the FBC model. Consequently, the analgesic potencies of
oxycodone and morphine are consistent with their profiles ofMOR activation in supraspinal
sites in the FBC model.
      Ofthe regions examined in this study, the PAG and mTH are thought to play
important roles in the analgesic effects of opioids, The PAG is part of the descending
analgesic pathway, and morphine suppresses the release of the neurotransmitter
y-amino-butyric acid (GABA) from neurons in the PAG i). ln the mTH, the stimulation of
MOR by opioids results in an increase of inwardly rectifying potassium channel current,
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which hyperpolarizes the cell and changes its firing pattern on the postsynaptic membrane 8).
The unique MOR activation profiles in the PAG and mTH with bone cancer pain may result
in the distinct in vivo analgesic potency of oxycodone.
      A chapter 2 using a neuropathic pain model reported that morphine-induced MOR
activation in the PAG, thalamus, and spinal cord did not differ significantly between
sham-operated and sciatic nerve-Iigated mice. In chapter 3, on the other hand, the maximum
activation ofMOR by morphine was attenuated markedly in several regions in the FBC model,
These results suggest that the function of MOR is differentially modulated depending on the
type ofpain.
      There are reports that the anti-nociceptive effect ofoxycodone is antagonized by
nor-BNI, a KOR antagonist, at a dose that did not affect the anti-nociceptive effect of
morphine in two rat neuropathic pain models 64' 79). This suggests that oxycodone produces its
analgesic effect by acting on the KOR. Conversely, several different groups reported that
oxycodone-induced anti-nociception is mediated by the MOR, and that oxycodone binds
selectively to MOR 36' 76). There is a possibility that the discrepancies ofthe responsible
receptors for the oxycodone effect might be due to the different routes ofadministration.
Since oxycodone is metabolized to oxymorphone, an active metabolite, by the peripheral
administration, the oxycodone-induced pharmacological effect may be resulted from both
oxycodone and oxymorphone. It has been reported, however, that both oxycodone- and
oxymorphone-induced anti-nociception was mediated by MOR rather than KOR 36). These
studies suggest that the difference in the administration route does not simply account for the
different roles of the MOR and the KOR in the opioid analgesic effects. In the present study, I
showed that increased GTPyS binding by oxycodone and morphine was antagonized by
P-FNA, but not by nor-BNI. My data are consistent with the idea that the pharmacological
effects, e.g., analgesic effects, ofboth oxycodone and morphine are mediated via the MOR.
      Finally, this study showed that the effects ofoxycodone and morphine are modulated
differently in bone cancer pain, and that MOR activation by oxycodone in brain regions
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related to pain signalling was attenuated less as compared with the effects ofmorphine.
Consistent with this, the overall analgesic potency of oxycodone was stronger than that of
morphine when they were administered intracerebroventricularly in the FBC model.
Therefore, the modulation ofMOR function under bone cancer pain appears to be one ofthe
mechanisms underlying the unique analgesic profile ofoxycodone, and such modulation may
determine analgesic efficacy of the particular opioid on chronic pain.
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                             General Conclusion
      The above findings lead to the following conclusion:
In Chapter 1:
      I showed that oxycodone, morphine and fentanyl intrinsically possess unique relative
efficacy for different pharmacological effects. It is, therefore, important to understand
respective pharmacological profiles ofthose opioids for the appropriate use. Although the
margins among anti-nociceptive effect and respective pharmacological effects observed in the
present study do not directly represent the margins in a clinical setting, these results provide
an important suggestion in the clinical opioid use to control pain and adverse effects.
In Chapter 2:
      I showed that oxycodone possesses high affmity and agonist activity for MOR in the
mouse brain. Taken together, the oxycodone-induced anti-nociception is mainly mediated
through MOR in the CNS, and oxycodone can be classified as the preferential MOR agoinst.
These findings provide further evidence that treatment with oxycodone produces a profound
antinociceptive effect under a neuropathic pain-like state, with a less or less ofa rewarding
effect. Furthermore, the reduction in G-protein activation induced by M-6-G in the spinal cord
and PAG may, at least in part, contribute to the suppression of the anti-nociceptive effect
produced by morphine under a neuropathic pain-like state.
In Chapter 3:
      Finally, this study showed that the effects of oxycodone and morphine are modulated
differently in bone cancer pain, and that MOR activation by oxycodone in brain regions
related to pain signalling was attenuated less as compared with the effects ofmorphine.
Consistent with this, the overall analgesic potency of oxycodone was stronger than that of
morphine when they were administered intracerebroventricularly in the FBC model.
Therefore, the modulation ofMOR function under bone cancer pain appears to be one of the
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mechanisms underlying the unique analgesic profile of oxycodone, and such modulation may
determine analgesic efficacy of the particular opioid on bone cancer pain.
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